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 Members of the cathepsin family of cysteine proteases are gaining interest as potential 
imaging biomarkers and drug targets due to their multifunctional roles in a range of diseases such 
as cancer, asthma and arthritis. Cathepsins are also involved in important regulatory processes such 
as cell recycling, prohormone activation, and wound healing. Developing imaging agents with the 
ability to assess cathepsin activity in vivo is important for identifying the specific roles these 
enzymes have in disease processes. We report here novel prodrug-inspired probes for Cathepsins B 
and L that employ weakly basic aminoquinoline reporter groups intended to be lysosomotropic 
once released from the enzyme, meaning they are expected to be retained in the acidic lysosome 
where the majority of cysteine cathepsins are primarily active. To evaluate this approach to probe 
design we first synthesized a series of prodrug inspired substrates using the self-immolative linker 
p-aminobenzyl alcohol conjugated to four different aminoquinolines as potential reporters of 
enzyme activity. We then developed a convenient HPLC method to estimate kcat/KM values for well-
established fluorogenic substrates to first validate our new HPLC method. Once a reliable HPLC 
method was developed for fluorogenic substrates consistent with data obtained on a plate reader, 
we then determined kcat/KM values for all novel quinoline-based probe candidates. All compounds 
were excellent substrates of both CTB and CTL, and three candidates were hydrolyzed with 
particularly efficient kcat/KM values by CTL.  This suggests that efficiently hydrolyzed prodrug-
inspired probes bearing aminoquinoline reporters could potentially be adapted into substrate-
based PET imaging agents which offer an amplification of signal and reporter immobilization in the 
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Chapter 1: Introduction 
 
 
 The theme of this thesis is the synthesis and enzymatic assay of substrate-based probe 
candidates for imaging cathepsins involved in aggressive cancer. The results of the project are 
provided as a Manuscript in Chapter 4, along with specific procedural details and supporting 
information. Preceding Chapter 4 is a Literature Review providing background information 
which contextualizes the thesis and explains the purpose and utility of substrate-based probes 
for molecular imaging of cathepsin activity. Theory, methodology, and rationale not covered in 
the Literature Review or Manuscript are provided in the Methodology section. Finally, the 
Conclusions and Future Work section summarizes the results and suggests directions for 














Chapter 2: Literature Review 
 
 






 Molecular imaging is a rapidly growing field with significant implications of how 
researchers and clinicians understand, predict, and respond to disease.1 While anatomical 
imaging has always been crucial in providing macroscopic physical information in relation to 
health and disease, molecular imaging (MI) provides important information on biochemical 
processes. Anatomical imaging techniques such as X-Ray, computed tomography (CT), and 
magnetic resonance imaging (MRI) provide important spatial information on size, shape, and 
density of organs and tissues. In contrast, molecular imaging can noninvasively provide 
functional, quantitative, and even kinetic information of biochemical characteristics.1 These 
biochemical characteristics are referred to as biomarkers and can serve as diagnostic or 
prognostic indicators, but they can also predict or reveal in vivo response to targeted therapies 
in both the preclinical and clinical settings. Molecular imaging provides researchers with a tool 
for understanding disease-promoting processes and developing targeted therapies2,3, while 
helping clinicians to characterize the pathology of a given individual or their response to 
treatment early on at the biochemical level.4 Key biochemical changes typically happen prior to 
anatomical changes1, central to the diagnostic and prognostic power of molecular imaging.5 The 
ability to noninvasively quantify biochemical processes in vivo is the essence of molecular 
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imaging and the reason for its growing importance in predicting and evaluating therapeutic 
response early after initiating therapy. 
 
 
2.1.2: Nuclear Imaging and PET 
 
 
 The nuclear imaging techniques single photon computed tomography (SPECT) and 
positron emission tomography (PET) are the most clinically relevant of the MI modalities.4,6,7 
While functional MRI (fMRI) is emerging as a tool for molecular imaging, the use of fMRI 
remains largely preclinical due to limited sensitivity in the detection of molecular contrast 
agents and limited temporal resolution.8 Optical imaging using near-infrared fluorescent (NIRF) 
tags is also used preclinically and to a less extent clinically, but due to poor imaging depth it is 
largely limited to shallow imaging of small animals or ex vivo imaging of tissues or organs.1 
Functional ultrasound (fUS) is currently limited to the use of contrast microbubbles preclinically, 
and has yet to be translated for use in imaging molecular markers.4 PET and SPECT offer 
unlimited depth penetration and are also the most sensitive of the molecular imaging 
techniques.7,9 The picomolar sensitivity of PET means it is not only clinically powerful but also 
minimally invasive since only trace amounts of imaging agent are required to produce high 
contrast images. 
 Highly sensitive molecular imaging with PET is similar in premise to SPECT, but the two 
modalities differ in the radionuclides used.7 A sub-microgram amount of radiolabeled imaging 
agent, also known as a tracer, is injected into the bloodstream. The tracer travels throughout 
the body but is designed to interact with a biomolecular target or metabolic pathway involved 
in disease.10 This results in an accumulation of the tracer in connection with a functional 
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biochemical process, and the tracer is quantitatively detected by means of the attached 
radionuclide. While both methods employ biologically active tracers tagged with radionuclides, 
the isotopes used in PET decay differently than those used in SPECT. 
 The positron-emitting radionuclides used in PET decay to release positrons which travel 
a negligible distance to annihilate with an electron. As a result of this annihilation, two 511 keV 
gamma rays are emitted 180° from one another and are coincidentally detected by a gamma 
camera.10 The single-photon emitting radionuclides used in SPECT decay to emit a single 140 
keV gamma ray directly. In both cases, detection of the gamma rays using 360° cameras allows 
for reconstruction of a three-dimensional image.11 The gamma rays have unlimited tissue depth 
penetration and allow the tracers to be detected with picomolar sensitivity9, meaning that only 
trace amounts of the imaging agent need to be injected. Toxicity issues are therefore less of a 
concern when compared to other imaging modalities, meaning that the endogenous 
biochemistry is unaltered by the tracer. This nontoxic and non-invasive nature is important for 
true insight into the underlying biochemistry of a given pathology. 
 While both PET and SPECT offer very high sensitivity and are minimally invasive, PET 
offers important advantages.12 To begin, the two coincident gamma rays emitted in opposing 
directions make it easier for PET cameras to define the precise location of the biomarker or 
radiolabeled tracer in three-dimensional space than does the single gamma ray emitted by 
SPECT radionuclides.13 The resulting spatial resolution for clinical PET is typically 3-4 mm, while 
that for µPET is approximately 1-2 mm.14 While the SPECT radionuclide 99mTc is currently used 
in 80% of nuclear medicine procedures owing to its convenient formation from the long-lived 
isotope 99Mo, the common isotopes used in PET (15O, 13N, 11C, and 18F) are more biologically 
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compatible and are easier to chemically incorporate into small biologically active tracers when 
compared to large atoms like 99mTc or 123I.15 Worldwide supply of the primary SPECT isotope 
99mTc has also been notoriously unreliable in recent years and alternatives are being sought due 
to reliance on weapons-grade uranium and five increasingly old reactors for its production.16,17 
Proximity to expensive cyclotron and radiopharmacy facilities is necessitated by the short half 
lives of PET isotopes, leading to challenges in tracer development and use. The resulting main 
disadvantage of PET imaging is the current limited availability of clinically approved imaging 
agents. 
 
2.1.3: PET Imaging Agents and Applications 
 
 
 New biomarkers are constantly being identified as important indicators of disease, 
especially in recent years.18 This has created great demand for the development of novel 
imaging agents intended to target new biomarkers for research and clinical purposes. 
Biomarkers can include biomolecular protein markers overexpressed in association with disease 
such as receptors, integrins, enzymes, or antibodies.14 Biomarkers can also include 
physiochemical or phenotype characteristics such as oxygenation, perfusion, and amyloid 
plaques.9,19-21 Inspiration for the design of novel imaging agents is based on structural 
biochemistry of the target or microenvironment, endogenous substrates of the biomarker, 
computational chemistry, or current probes and drugs.14 Any combination of these approaches 
may be used to rationally design probes specific to their target. The probe must also be 
chemically and metabolically stable prior to reaching the target, and must overcome delivery 
6 
 
barriers such as cell membranes, antibody recognition, rapid excretion, and phagocytosis.22 
Also important to the design of tracers is the radioisotope used for labelling. 
 The most commonly used PET isotopes are 15O, 13N, 11C, and 18F, with have half lives of 
2, 10, 20, and 110 minutes respectively.15 With the exception of 18F, their clinical utility largely 
comes from the fact that they are radionuclides of elements with naturally occurring isotopes 
and can therefore replace the stable nuclide in naturally occurring compounds. The isotope 18F 
however can be employed in tracers as an isostere for hydroxyl groups, and because of its small 
size it can be incorporated into high affinity ligands or substrates for protein biomarkers. As a 
result of the short half lives of PET isotopes however, there are important practical 
considerations in the development of imaging agents. The half-life of the radionuclide used 
must be suitable for practical considerations of synthesis, shipping, administration, and the 
pharmacokinetic profile of the tracer.14,23,24 Interest has grown in the longer-lived PET isotopes 
64Cu and 89Zr due to the ability to ship them to distant locations and their potential to be 
incorporated into imaging agents with longer serum half-lives such as antibodies. PET tracers 
however generally need to be synthesized, purified, and analyzed within minutes, while most 
synthetic reactions used in medicinal chemistry occur on the hour or day time scale and are 
therefore impractical in radiotracer synthesis. The short half lives of positron emitters therefore 
not only create the need for proximity to a cyclotron and radiopharmacy, but strategic 
approaches to tracer design and synthesis are needed as well. Although these factors make 
tracer development a great challenge, there are both preclinical and clinical applications of PET. 
 Strategically designed tracers that target specific biomolecules can be used in the 
preclinical setting to help understand the underlying biochemistry of disease. Not only are new 
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biomarkers and tracers constantly being investigated for their utility in understanding disease 
characteristics, MI can also be used for therapeutic target validation and drug assessment at 
the preclinical stage.2,3,25 Many drugs and chemotherapeutic agents that target markers 
associated with disease have been radiolabeled for PET studies, allowing for the noninvasive 
assessment of their biodistribution and pharmacokinetics preclinically. Examples include 68Ga-
Trastuzumab which targets epidermal growth factor receptor type II (HER2) positive breast 
cancer, 11C-Tarceva which targets epidermal growth factor receptor, and 18F-Tamoxifen which 
targets the oestrogen receptor.4 Few drug candidates are ever translated for clinical use, and 
most fail during clinical trials. This results in fruitless drug development costs and has led to an 
increased demand for early noninvasive screening procedures in humans2. So not only are new 
biomarkers and imaging agents constantly being investigated for the purpose of understanding 
disease, PET will also continue to play an increasingly important role in the development of 
novel therapeutics for the clinic. 
 PET currently has clinical applications in oncology, neurology, and cardiology,26-28 where 
it is involved in diagnosis, prognosis, staging, and the prediction and evaluation of therapeutic 
response.13 PET imaging has been used to diagnose malignant cancer, and it has been used to 
differentiate between recurring tumors and necrosis due to radiation therapy.29,30 Cardiac 
function, perfusion, and viability have all been assessed using PET.31,32 A patient's risk of 
developing coronary heart disease (CAD) can be determined, and PET can also help determine 
which patients are likely to benefit from heart bypass surgery. PET has also been used in 
monitoring response to therapy as demonstrated using [18F]Fluoromizonidazole to image the 
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hypoxic environment of tumors in response to chemotherapy, and fluorodeoxyglucose (18F-
FDG) to gauge therapeutic response in patients suffering from lymphoma. 
 18F-FDG is the most widely-used PET radiopharmaceutical in the world.33 It is used to 
assess glycolytic metabolism, especially in growing tumors that have an increased demand for 
glucose due to the Warburg effect34. It is a radiolabeled derivative of glucose, employing the 
positron emitting radionuclide 18F in the 2' position in lieu of the hydroxyl group as seen in 
Figure 1. FDG is rapidly taken up by tumor cells by the GLUT transport proteins and 
phosphorylated by hexokinase in the same way that glucose is in the first step of glycolysis. 
Phosphoglucose isomerase, the second enzyme involved in the glycolytic pathway, cannot 
isomerize 18F-FDG-6-phosphate since the 2' hydroxyl group has been replaced by 18F. By virtue 
of being phosphorylated, 18F-FDG-6-phosphate is ionically charged and can no longer be 
pumped out of the cell by the GLUT transport proteins nor can it passively diffuse across cell 
membranes. As a consequence, 18F-FDG-6-phosphate is cell impermeable and accumulates in 
hyperglycolytic tissues and organs. Indeed, FDG uptake in suspected cancer lesions is correlated 





Figure 1: Imaging glucose metabolism using FDG-PET. Highly metabolic tumor cells have a high demand 
for glucose relative to other cells. 18F-FDG is rapidly influxed by the GLUT transporter proteins and 
phosphorylated by hexokinase in a similar manner to glucose. 18F-FDG-6P is ionically charged and 
therefore cell impermeable, allowing for PET imaging of aggressive cancer. 
 
 
 The many applications of FDG-PET are due to its ability to image glycolytic activity, 
which is an aberrant metabolic process in many pathologies. However to understand how 
specific pathways or biomolecules contribute to other diseases and disease processes, new 
tracers targeting other potential biomarkers are urgently needed. FDG, however, demonstrates 
the utility in designing tracers to be efficient substrate-based probes which release radioactive 






2.2: Cysteine Cathepsins as Biomarkers for Aggressive Cancer 
 
2.2.1: Proteases and Cysteine Cathepsins 
 
 
 Protein hydrolysis is a key process in all living cells carried out by a diverse class of 
enzymes called proteases that are involved in many aspects of health and disease.35 Due to the 
diverse nature of proteins as ubiquitous biomolecules, there are many preclinical and clinical 
implications of proteolytic activity.35,36 There are five general protease classes; serine, cysteine, 
aspartyl , threonine, and metalloproteases, all of which are grouped according to the 
mechanism of catalysis employed in the enzyme active sites.37 Within the active site of aspartyl 
and metalloproteases, a water molecule is promoted as the nucleophile in hydrolysis of the 
peptide bond. However in the case of serine, threonine and cysteine proteases, the respective 
eponymous residues themselves are involved in nucleophilic attack of the peptide bond, 
promoted by one or more amino acids acting as general bases in close proximity to the active 







Scheme 1: Hydrolysis of a peptide bond by cysteine proteases. Histidine increases the nucleophilicity of 
the cysteine thiol group, which upon nucleophilic attack of the peptide carbonyl carbon forms a 
tetrahedral intermediate prior to forming the acetylated enzyme. The thioester is subsequently 






 According to Schechter and Berger nomenclature38, peptides are cleaved between the 
P1 and P1' amino acid residues by definition, which relative to the scissile bond are located 
toward the amino- and carboxy-terminus of the peptide respectively. The amino acid residues 
of the peptide are termed P1, P2, P3... as counted toward the N-terminus from the scissile bond 
and P1', P2', P3'... as counted toward the carboxy-terminus.
36 The corresponding recognition 
subsites within the protease that accept the substrate residues are deemed S1, S2, S3... or S1', 
S2', S3'... in a complementary fashion to the P and P' residues of the peptide as shown in Figure 
2. The affinity of these noncovalent interactions depends on how well the subsites accept the 
particular residues of the peptide. Within the cysteine cathepsin family of proteases, structural 
homology and similarity in specificity is seen across most of the enzymes. 
 
Figure 2: Schechter and Berger nomenclature for a protease active site and complimentary substrate.  
Both the enzyme subsites (S) and peptide residue (P) are numbered relative to the scissile bond. The 
S1'...SN' subsites and corresponding P1'...PN' residues are numbered ascendingly toward to C-terminus of 
the peptide from the scissile bond, while the S1...SN subsites and P1...PN residues are numbered 
ascendingly toward the N-terminus of the peptide. 
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 The papain family of cysteine proteases is a well-studied group of hydrolases which 
encompasses eleven human enzymes known as cathepsins. Cathepsins B, C, F, H, K, L, O, S, V, 
W, and X are all involved in intracellular proteolysis, and the majority of these cysteine 
cathepsins evolved to be located within small organelles dedicated to catabolism and cellular 
debris recycling called lysosomes.39 Cathepsin activity is therefore largely dependent on and 
limited to the acidic milieu of the lysosome, which has a pH ranging from approximately 4-5.40,41 
Cysteine cathepsins are also active to a certain extent in the acidic endosomes, which transport 
extracellular material engulfed by endocytosis to the lysosome.42 They all have important 
physiological functions and are involved in such processes as immune response, hormone 
processing, catabolism, and even bone development.39,43 
 As with most proteases, the regulation of endogenous activity is not only dependent on 
location, but other posttranslational processes as well.  At the expression level, cysteine 
cathepsins are synthesized as "proenzymes" or zymogens which are mainly inactive until 
undergoing protease activation within the lysosome. Activation of the proenzymes to their 
mature fully-active counterparts can be executed by the residually active proenzymes 
themselves, known as autocatalysis, or by other proteases. The activity of subsequently mature 
cathepsin is further controlled by differential expression of endogenous inhibitors, including the 
small protein competitive inhibitors of the cystatin, thyropin, and serpin families. The functional 
activity of these important enzymes is therefore largely regulated at the posttranslational level 
and is secluded to lysosomes under normal conditions. In association with numerous 
pathologies however, their aberrant expression, activity or delocalization can lead to or 
promote diseases such as aggressive cancer, arthritis, and atherosclerosis.44,45 This highlights 
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the importance of techniques that image functional cathepsin activity in disease-promoting 
processes and not just expression levels alone. 
 
2.2.2: Cathepsin B and Aggressive Cancer 
 
 
 There is growing evidence that the overexpression of cathepsins in various cancers is 
associated with tumor metastasis, the primary cause of death among cancer patients.46 
Metastasis is the spread of cancer to distant tissues and organs from the original location, and 
the likelihood of a tumor to spread from its primary site is referred to as its metastatic 
potential. Metastasis of a tumor to a secondary location involves several steps.47,48 The first 
step is invasion, where invasive tumor cells break away from the primary aggressive tumor and 
eventually migrate toward blood vessels.49,50 The tumor cells must then enter the bloodstream 
or lymphatic system, termed intravasation, which serves as their primary means of migration to 
other organs. Upon surviving circulation and arresting at a given location the tumor cells must 
extravasate, or exit the bloodstream or lymphatic system. Depending on their ability to invade 
and proliferate in the new tissue, the cancers cells can then colonize to form a secondary 
tumor.51 This spread of cancer from one location to another is believed to account for 90% of all 
cancer deaths, as opposed to tumor cells residing at one inopportune site for a prolonged 
period of time.48 Therefore the ability to characterize the metastatic potential or aggressiveness 
of a patient's tumor at an early stage would have valuable prognostic applications and could aid 
in determining the aggressiveness of therapy required.52,53 
 The overexpression and delocalization of cathepsin B is believed to be involved in 
invasion as seen in Figure 3, the earliest stage of metastasis.46 Like most cathepsins, CTB is 
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optimally active in and isolated to the lysosome under healthy conditions. However its 
increased activity at the invading edge of a tumor and within the extracellular matrix is known 
to contribute to a tumor's ability to become invasive and reach the bloodstream.54 While CTB is 
known to degrade collagen and fibronectin of the extracellular matrix (ECM) producing a 
permissive region for cancer cells to invade, it is also believed to indirectly contribute to ECM 
degradation through the activation of other proteases and the degradation of protease 
inhibitors. Extracellular CTB is believed to cleave cell adhesion proteins, resulting in tumor cell 
mobility. An increase in extracellular CTB activity has been correlated with metastatic potential 
and poor patient prognosis.55-57 Further complicating is the fact that CTB can not only blunt 
tumor response to chemotherapy58, but actually induce tumor growth in reaction to 
chemotherapy.59 On the contrary, aberrant intracellular CTB activity is known to promote 
apoptosis in tumor cells and is associated with favorable patient prognosis.60-62 Given the 
apparent role CTB has in promoting the invasion of aggressive cancer, great efforts have been 
made to develop CTB-targeted prodrugs as potential anti-cancer therapeutics. The ability to PET 
image cathepsin activity would therefore be valuable not only in validating CTB as a legitimate 





Figure 3: The role of Cathepsins B and L at the invading edge of an aggressive tumor. While CTB and 
CTL activity is normally isolated to the lysosome in healthy cells, their aberrant expression and activity in 
the tumor microenvironment is known to promote invasion, the first step in tumor metastasis to a 
secondary site. CTB and CTL are known to degrade the extracellular matrix (ECM) and cell adhesion 
proteins, creating a permissive path for intravasation to the bloodstream. 
 
2.2.3: Cathepsin B as a Targeted Biomarker 
 
 
 To evaluate functional cathepsin activity in vitro and in vivo as opposed to relying on 
expression levels alone, two strategies have emerged. The first approach uses activity-based 
inhibitors that are designed to covalently label the target active site of catalytically active 
enzymes in a 1:1 ratio. They contain a targeting moiety that provides affinity for the target 
active site linked to a reactive group (or "warhead") and either a fluorescent tag or PET 
radioisotope. By virtue of alkylating the active site, mechanism-based probes inherently offer a 
means of signal localization, therefore accumulating in the immediate local tissues and organs 
that have high enzyme activity. A drawback of the activity-based approach is that covalent 
labelling of the enzyme active site prevents further enzyme processing of more probe 
molecules by the same enzyme. This could result in a decrease in contrast since physiological 
levels of enzyme may not be high enough to generate sufficient signal-to-noise for detailed PET 
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images. Substrate-based probes, on the other hand, are not covalently retained in the active 
site but rather are recognized and catalytically processed by the target enzyme.63 This 
potentially offers an amplification of signal as one active site is capable of turning over 
thousands of tracer molecules per minute. Once freely released from the active site however, 
substrate-based probes must rely on different mechanisms of local retention than the covalent 
nature of activity-based probes. 
 Activity-based probes (ABPs) for the purpose of imaging cysteine cathepsin activity were 
first reported by Bogyo and coworkers who developed fluorogenic mechanism-based inhibitors 
employing the reactive acyloxymethyl ketone (AOMK) group.64 Until the AOMK group reacts 
with the cysteine active site through the mechanism shown in Scheme 2(a), the fluorescent 
signal of the probe is inherently quenched as shown in Scheme 2(b). In other words, the probes 
become fluorescent only after being recognized and hydrolyzed by the target protease. The 
inherent fluorescence of probes is low since the Cy5 fluorophore and internal QSY21 quencher 
are held in close proximity to each other but on opposite sides of the cathepsin-recognized 
bond.64 The QSY21 quencher is conjugated to the aryl leaving group of the AOMK warhead and 
diffuses from the vicinity of the Cy5-labelled active site once released by the cysteine protease. 
Despite the elegance of these "smart" fluorescent probes that turn on only once activated, they 
lacked specificity for either CTB or CTL, and fluorescent probes are intrinsically limited to small 
animal studies64 and tissue surfaces65 due to very poor imaging depth.  Nonetheless, derivatives 
of these quenched activity-based probes (qABPs) were radiolabeled for PET studies in animal 
models of cancer. Along with removal of the QSY21 quencher group to yield an underivatized 
AOMK warhead, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was 
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conjugated either at the N-terminus of the peptide or in lieu of the Cy5 moiety to allow for 
coordination of the 64Cu radiolabel by chelation.66 Although the derivative employing the N-
terminus DOTA-64Cu provided modest tumor uptake, both tracers exhibited high liver uptake 
and hepatobiliary clearance resulting in poor images since the entire abdomen of the mouse 
was radioactive. This is likely due to the high lipophilicity of these tracers which is typically 
avoided in most PET probes since renal clearance and elimination of the radiotracer in the 
bladder is preferable. While demonstrating the ability to PET image cysteine cathepsins with an 
AOMK warhead, these tracers were not shown to be specific for any given cathepsin and lacked 















Scheme 2: Covalent labeling of cathepsin active sites using AOMK inhibitors. (A) Mechanism of 
inhibition by AOMK inhibitors; (B) Quenched activity-based probes as employed by Bogyo and 
coworkers. Prior to enzymatic labelling, the fluorescence of the Cy5 moiety is quenched due to proximity 
of the QSY21 quencher on the opposite end of the cathepsin-recognized linkage. An enzyme labelled in 





 To evaluate a signal amplifying substrate-based approach to NIR fluorogenic probes, Kim 
and coworkers developed a polymer nanoprobe composed of repeating glycol chitosan 
monomers which are conjugated to either a tumor-targeting hormone or CTB-targeting peptide 
substrate in an alternating fashion.67 At the N-terminus of the CTB-targeting peptide is the 
Cys5.5 fluorophore which is quenched by the BHQ-3 quencher toward the C-terminus on the 
other side of the scissile bond. The scissile bond is hydrolyzed by CTB to free the fluorophore 
from close proximity to the quencher, activating the fluorescent signal. This occurs at multiple 
locations along the polymer to yield strong fluorescence in correlation with CTB activity. 
Unfortunately, due to poor blood clearance and poor cell permeability, a nanoparticle approach 
is largely dependent on the enhanced permeability and retention (EPR) effect of the tumor 
environment.68 That is, the enhanced permeability of tumor vasculature and the suppression of 
lymphatic filtration can improve the ability of macromolecules to spontaneously enter and 
reside in tumors. However, heterogeneity of the EPR effect within and between tumor types 
has hampered the development and utility of imaging agents and drugs employing a 
nanoparticle design.68 So while substrate-based polymers such as those explored by Kim might 
offer greater sensitivity over activity-based inhibitors, small molecule probes typically have 
superior pharmacodynamic properties for clinical imaging and are easier to prepare and purify, 
satisfying the strict regulations associated with PET tracers intended for human use. 
 Small molecule SBPs such as the ones reported herein potentially offer the advantage of 
signal amplification, but a major drawback commonly encountered is the rapid diffusion of the 
reporter molecules from the site of activation. Cathepsins, however, are primarily active in the 
acidic lysosomes of cells, and this low pH can potentially be exploited to enhance the retention 
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of reporter groups released within this environment. Not long after discovering the lysosome 
six decades ago, deDuve reported that weakly basic amines spontaneously accumulate at high 
concentration after becoming ionically charged in the acidic environment.69,70 This ionic 
trapping in the lysosome, as seen in Figure 4, results from membrane impermeability and has 
come to be known as lysosomotropism.71 SBPs bearing lysosomotropic amine reporter 
molecules that are freely released from the enzyme upon hydrolysis of the substrate could 
potentially offer a means of signal localization in addition to an amplification of signal. 
 
 
Figure 4: Lysosomotropism of a lipophilic amine. A lipophilic amine has the ability to passively diffuse 
across membranes, but depending on its pKa a weakly basic amine may become primarily protonated 
once reaching the acidic lysosome and therefore retained. The R group can also be a lysosome-targeting 






2.2.4: Our Approach to Imaging Cathepsins 
 
 
 Indeed small molecular probes tend to have rapid biodistribution and clearance 
properties and are easier to prepare and purify when compared to nanoparticles.68,72,73 In 
addition to superior biodistribution and clearance properties, small molecules are also less 
prone to elicitation of immune response.74 Ease in preparation is important for optimizing the 
structures of probe candidates, and the radiolabelling process is typically more direct and rapid 
for small molecules with relatively few functional groups.74 In particular, small molecular 
substrate-based probes that release locally retained species as opposed to activity-based 
probes that inhibit the enzymatic target potentially offer the advantage of signal amplification. 
To this end, we have developed small molecule probes that are designed to release retained 
reporters at the target site only after being processed and released by CTB or CTL, rather than 
functioning as activity-based inactivators that achieve retention by means of covalently 
inhibiting the active site of the target. 
 Designed to be selective for CTB or CTL, we chose to synthesize probe candidates 
employing a three-component design. One of various aminoquinoline reporter groups is 
connected to a dipeptide substrate via the self-immolative linker PABA. Analogous to prodrugs 
that are activated to release a drug as seen in Figure 5, the substrate-based probes reported 
herein are efficiently hydrolyzed by CTB and CTL to release one of various aminoquinolines 
which should be ionically charged and retained within the lysosome. Only upon enzymatic 
cleavage of the dipeptide from the linker-reporter unit does the PABA linker spontaneously 
decompose to release a locally retained reporter. The PABA linker is commonly used in the 
design of prodrugs, and until recognition and cleavage by CTB within the lysosome of the cell, 
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the intact probe should be cell permeable and travel throughout the body to reach the target 
site. 18F-labelled lysosomotropic reporter groups could prove useful toward developing 
cathepsin substrate-based PET agents that are retained in their immediate environment. 
 
 
Figure 5: Prodrug-inspired substrate based approach for cathepsin probes. Prodrugs are enzymatically 
processed at a target site to release an active drug. In an analogous fashion, the prodrug-inspired probe 
candidates employed herein are efficiently hydrolyzed by CTB and CTL to release one of various 
aminoquinoline isomers, which are all expected to accumulate in the cathepsin-occupied lysosome and 
can foreseeably be 18F-radiolabeled. Such substrate-based probes offer an amplification of signal 
compared to activity-based inactivators while still potentially offering a mechanism of signal localization. 
 
 The dipeptide portion of the probe is designed to provide affinity and specificity for CTB 
or CTL. There are eleven human cathepsins and achieving specificity to any of them is a 
challenge due to structural homology within the family. The majority of cathepsins prefer a 
positively charged species at the P1 position of the substrate and a hydrophobic species at the 
P2 position
75, however CTB is unique in that it can also accept a positively charged amino acid at 
the top of its S2 pocket. This is due to the presence of a glutamic acid residue at the top of its S2 
pocket. To take advantage of this substrate preference, we designed probes with lysine as the 
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amino acid in both the P1 and P2 positions as seen in Figure 6. Analogs employing phenylalanine 
at the P2 position were also prepared to be substrates of CTB and CTL. The probes are protected 
at the N-terminus using carboxybenzyl (Z) as this has been shown in literature to be well 
accepted by the P3 pocket of CTB. Using lysine in lieu of arginine, which is employed in the 
commercial substrates Z-FR-AMC and Z-RR-AMC, is advantageous for synthetic reasons as 
discussed in Chapter 3. 
 
Figure 6: The general structure of the novel prodrug-inspired probe candidates reported herein. At the 
P1 and P3 positions of the peptidic probe candidates are lysine and carboxybenzyl respectively, both 
shown to be well accepted by the S1 and S3 subsites of the enzyme. At the P2 position is either 
phenylalanine, known to be well-tolerated by most cathepsins, or lysine, hopefully exploiting the unique 
ability of CTB to accept positively charged groups within the S2 site. The PABA linker conjugates the 
dipeptides to one of various aminoquinolines (3-AMQ, 4-AMQ, 5-AIQ, or 6-AMQ). 
 
 The PABA linker has been used in the design of prodrugs76-78 and fluorogenic79,80 
enzymatic substrates. The amine of PABA can be condensed with the carboxy-terminus of a 
peptide specifier to form an amide linkage, and phenol- or aniline-based drugs can be 
subsequently conjugated to the benzylic alcohol of PABA via stable phenolic or carbamate 
linkages. Following hydrolysis of the specifier-PABA amide bond, self-immolation of a PABA-
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drug carbamate bond occurs spontaneously and rapidly.81 The spontaneous hydrolysis of the 
benzyl-carbamate bond following enzymatic cleavage of the specifier-linker bond is due to 
conversion of the weakly electron-donating acyl-amido group to the relatively strong electron-
donating amine group. This extra electron density within the π system promotes the 
development of a para-azaquinone-methide through a 1,6-elimination82, allowing for 
spontaneous immolation of the benzyl-carbamate linkage. The resulting carbamic acid is 
unstable and spontaneously decomposes to rapidly yield carbon dioxide and the aniline-based 
drug. This rapid self-immolation has been taken advantage of in both prodrugs and 
profluorophore substrates. 
 In the case of prodrugs, a linker such as PABA has been used to conjugate a specifier to a 
drug in order to improve intermolecular bond stability or provide the prodrug with greater 
affinity for the target enzyme.79,81,83 In the design of fluorogenic enzymatic substrates, the use 
of PABA in conjugating phenol- or aniline-based fluorophores  by means of phenolic or 
carbamate linkages may inherently quench their fluorescence prior to enzymatic recognition.79 
Our group has previously demonstrated that when introduced into fluorogenic peptides, PABA 
improves recognition and cell permeability while maintaining efficient turnover of 
profluorophore probes by CTB.84 
 There are several advantages of incorporating the prodrug-inspired PABA linker into 
three-component probe candidates for CTB. The prodrug inspired PABA linker enables the 
conjugation of the aniline based aminoquinoline reporters through a chemically and 
metabolically stable carbamate linkage. Without PABA, a peptide directly derivatized with an 
aminoquinoline reporter would form a reactive amide that is likely to be processed by a 
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number of proteases or esterase enzymes. Furthermore, PABA can extend into the active cleft 
of CTB, preserving recognition when bulky substituents such as drugs or contrast agents are 
placed at the P2' position. Indeed, prodrugs employing PABA as a self-immolative linker have 
not only been shown to be efficiently processed by cathepsins to release an active drug, but are 
serum stable as well.76,85 
 The novel probe candidates herein are designed to release a reporter molecule that is 
retained in the lysosome where cathepsins primarily reside. We hypothesize that using a 
substrate-based approach will take advantage of the catalytic power of the target protease 
while also using aminoquinolines as lysosomotropic reporter molecules that will accumulate 
within the lysosome where most cysteine cathepsins are located. This approach will potentially 
provide both amplification of signal and reporter retention compared to an activity-based 
approach which inactivates the target enzyme. 
 Indeed, there are examples of PET imaging agents and therapeutics that have taken 
advantage of lysosomotropism for increased sensitivity or selectivity toward their given targets. 
Lysosomal trapping as a mechanism of signal amplification in PET is demonstrated by [11C]N-
desmethyl-loperamide, which enters brains cells and accumulates in lysosomes therein only 
when the blood-brain barrier efflux protein P-glycoprotein is not functioning.86 The effect of 
lysosomotropism on drug biodistribution has been reported by several investigators71, and 
lysosomal sequestration of anticancer agents has been shown to promote cancer cell selectivity 
at least in vitro.87 The lysosomotropic epoxide-based cathepsin probe reported by Wright and 
coworkers88 is an activity-based inhibitor of the enzyme and therefore lack a mechanism of 
signal amplification similar to other activity-based probes mentioned. In addition, they would 
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potentially provide poor signal to noise if radiolabeled for PET studies because they accumulate 
in lysosomes regardless of cathepsin recognition. Although most cysteine proteases reside 
primarily in the lysosome, cathepsin substrate-based probes that employ lysosomotropic 
reporters have yet to be developed. 
 The four quinoline reporter groups we chose as reporter molecules and expected to be 
retained in the lysosomes are 3-aminoquinoline (3-AMQ), 4-aminoquinoline (4-AMQ), 5-
aminoisoquinoline (5-AIQ), and 6-aminoquinoline (6-AMQ), as seen in Figure 7. The 
approximate pH range of the lysosome is 4-541, while the weakly basic quinoline isomers 3-
AMQ, 4-AMQ, 5-AIQ, and 6-AMQ have pKa values of 4.95-5.0, 9.0-9.17, 5.59-6.0 and 5.63 
respectively.89,90 The lysosomotropic properties of 3-AMQ, 4-AMQ, and 5-AIQ have been 
reported in literature, determined by treating living cells with low concentrations of each 
amine.90 The ratio of [lysosomal]/[cytosolic] accumulation for 4-AMQ was reported as 
approximately 60, while that for 5-AIQ and 3-AMQ was approximately 25 and 4 respectively.90 
The pKa values of the individual quinolines correlate with these results and were hypothesized 
to determine the degree to which each accumulates in the low pH of the lysosome. Although 6-
AMQ is not reported in literature as being lysosomotropic, its pKa of 5.6 suggests that it is also 
likely to be ionized and retained within the lysosome. Employing lysosomotropic reporter 
molecules in such a way is a novel approach, and it is currently unclear how lysosomotropic 
behaviour would be influenced when each aminoquinoline is released by an enzyme directly 
within the lysosome. To evaluate this approach, a series of small molecule substrate-based 
probes bearing aminoquinoline reporter groups was developed along with a convenient HPLC 




Figure 7: The four quinoline isomers used as reporter groups in our substrate-based probes. For the 
purpose of assessing the ability to detect cathepsin activity using lysosomotropic reporter groups, 
amines with varying pKa were chosen which can all be conjugated to peptide substrates using similar 
chemistry.  3-AMQ, 4-AMQ, and 5-AIQ have been reported as being lysosomotropic when incubated 
















2.3: Summary and Scope of Project 
 
 
 Given the multifunctional roles of cathepsins in health and disease, imaging agents with 
the ability to specifically assess cathepsin activity in vivo would be important for validating 
individual cathepsins as biomarkers of disease or drug targets. We report herein a series of 
novel prodrug-inspired peptidic probes for CTB and CTL that employ aminoquinoline reporter 
groups intended to be lysosomotropic once released from the enzyme, meaning they are 
expected to be locally retained where the majority of cysteine cathepsins are primarily active. 
These substrate-based probes do not covalently label the enzyme active site but rather are 
freely released upon hydrolysis, potentially offering a means of signal amplification in addition 
to signal retention. To evaluate this approach to probe design we developed a convenient HPLC 
method for determining kcat/KM values for commercial fluorogenic substrates. The kinetic values 
of kcat/KM obtained using the HPLC method were consistent with a fluorospectrophotometer-
based continuous assay using the well-established fluorogenic substrates. The same HPLC 
method was used to determine kcat/KM for each quinoline-based probe candidate reported 
herein. We hypothesize that this approach to probe design could be used to detect other 
enzyme families, and the HPLC assay developed could be conveniently applied to other 
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Chapter 3: Methodology 
 
 
 This chapter reviews the methods used in the following manuscript, with a focus on the 
underlying rationale and theory not covered therein. Specific procedural details are provided in 
the following manuscript of Chapter 4. 
 
3.1: Synthesis of Probe Candidates 
 
 
 For the purpose of evaluating a series of substrate-based molecular probes bearing 
aminoquinoline reporter groups, we sought a common route for their preparation. First, the 
two substrate-linker peptides Z-Phe-Lys(BOC)-PAB-OH and Z-Lys(BOC)-Lys(BOC)-PAB-OH are 
prepared using well-established peptide chemistry1. Each quinoline was then conveniently 
conjugated by means of isocyanation and subsequent coupling to the acidic hydroxyl group of 
PABA through a stable carbamate linkage. The quinolines 3-AMQ, 5-AIQ, and 6-AMQ are all 
converted to their respective isocyanates by phosgenations, while 4-quinolinecarboxylic acid (4-
QCA) is converted to its respective isocyanate by means of a Lossen rearrangement for 
incorporation as the 4-AMQ reporter group.2 Deprotection of the BOC groups was achieved 
rapidly in quantitative or high yield using 50% TFA:DCM. The use of lysine instead of arginine, 
an amino acid preferred at the S1 site of CTB and CTL, was chosen due to the convenient 
installation and removal of BOC protecting groups from the ε-amine versus protection and 






Scheme 3: Synthetic scheme of precursor peptides Z-FK-PAB-OH (7) and Z-KK-PAB-OH (12). (a) 
CuSO4•5H2O, BOC2O, H2O/acetone, RT, 12h; (b) 8-hydroxyquinoline, H2O, RT, 5h; (c) HO-Su, DCC, THF, 
0°C-RT, 12h; (d) NaHCO3, THF/H2O, RT, 16h; (e) EEQD, THF, RT, 16h; (f) H2SO4, ethyl acetate, RT, 1h; (g) 
Et3N, DMF, 0°C-RT, 16h 
 
 The activated precursors Z-Phe-O-succinimide (5) and Z-Lys-N-ε-BOC-O-succinimide (10) 
were prepared according to literature3 as seen in reaction (c) of Scheme 3. Commercially 
available Z-Lys(BOC)-OH•DCHA (8) was extracted to the free acid (9) using H2SO2, and along 
with commercially available Z-Phe-OH, the two were both converted to their respective 
succinimides using N-hydroxysuccinimide and DCC. For the purpose of being coupled to the 
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activated precursors (5) and (10) as the P1 moiety of all probe candidates, Lys(BOC)-OH (3) was 
also conveniently and inexpensively prepared according to literature4, although it can be 
purchased commercially if desired. Lys•HCl was converted to Lys2Cu as an intermediate using 
CuSO4•5H2O, followed by addition of excess di-tert-butyl dicarbonate in a one-pot procedure to 
yield (2). The unreacted pyrocarbonate is decomposed using methanol prior to filtering the 
precipitated [Lys(BOC)]2Cu product, after which the copper is quantitatively removed using 8-
quinolinol to furnish (3). 
 Coupling of (3) with either (5) or (10) was performed to provide either Z-Phe-Lys(BOC)-
OH (6) or Z-Lys(BOC)-Lys(BOC)-OH (11) respectively. Coupling of (3) with (5) was performed 
using NaHCO3 in water and THF
5, while (3) was coupled to (10) using TEA as the base and DMF 
as the solvent6. Both of the resulting peptides (6) and (11) were coupled with PABA using EEDQ 
in THF1, providing Z-Phe-Lys(BOC)-PAB-OH (7) and Z-Lys(BOC)-Lys(BOC)-PAB-OH (12). 
 Phosgenation of 5-AIQ in the presence of 4-dimethylaminopyridine was carried out over 
night in a procedure adapted from literature, and following extraction of the isocyanate it was 
coupled to 7 and 12 in yields of 34% and 21% respectively. While this procedure provided 
modest yields for 5-AIQ, it was ineffective in the coupling of 6-AMQ and 3-AMQ to 7 and 12. 
Isocyanation and subsequent coupling of both 6-AMQ and 3-AMQ is performed using a shared 
procedure adapted from literature7 as shown in Scheme 4. Conversion of either 6-AMQ or 3-
AMQ to their respective isocyanates is achieved using phosgene in the presence of 
triethylamine, and subsequent coupling to either 7 or 12 is performed in a one-pot fashion 
within hours. In this manner, 6-AMQ was coupled to 7 and 12 in yields of 24% and 16% 
respectively, while 3-AMQ was coupled to 7 and 12 in yields of 64% and 20% respectively. 4-
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quinolinecarboxylic acid (4-QCA) is converted to its respective isocyanate through a Lossen 
Rearrangement using carbonyldiimidazole and hydroxyl amine2, so as to be incorporated as the 
4-aminoquinoline (4-AMQ) reporter group. We chose 4-QCA as it is commercially inexpensive 
relative to its 4-AMQ counterpart yet is still conveniently coupled in a one-pot procedure with 7 
and 12 with yields of 27% and 19% respectively. 8-aminoquinoline failed to be converted to its 
isocyanate counterpart for coupling, probably due to the low nucleophilicity of its amine. 
 All resulting BOC-protected carbamates were deprotected using 50% TFA:DCM at ice 
bath temperature, rapidly providing the final probe candidates seen in Scheme 4. Deprotection 
was quantitative in all cases except in furnishing Z-K(TFA)K(TFA)-PABA-6AMQ and Z-
K(TFA)K(TFA)-PABA-4AMQ, which were obtained in yields of 82% and 88% respectively from 







Scheme 4: Conjugation of the four aminoquinoline reporter groups to 7 and 12. 3-AMQ, 6-AMQ, and 5-
AIQ are all converted to their respective isocyanates via phosgenation for convenient coupling to the 
acidic hydroxyl of 7 and 12. 4-quinolinecarboxylic acid (4-QCA) is converted to its isocyanate via a Lossen 
Rearrangement for incorporation as the 4-aminoquinoline reporter group. All BOC-protected 
carbamates are deprotected in quantitative or high yield using TFA:DCM. Yields are based on precursor 










3.2: Kinetic Evaluation of Probe Candidates 
 
 There are two common methods for determining kinetic parameters associated with 
enzymatic activity, although both rely on quantifying the formation of product or the 
consumption of substrate over a given amount of time. The first type of enzymatic assay is an 
end-point assay, where samples of the enzymatic reaction are stopped after given time points 
and the concentration of substrate or product is quantified. This is in contrast to a continuous 
assay, which employs a continuous or "live" reading of substrate turnover during the course of 
the reaction. Quantification of substrate turnover is typically based on the generation of a 
fluorescent signal as a result of enzymatic processing, or spectrophotometric detection of the 
product as a result of UV or visible light absorption. Fluorescent detection of product is typically 
more sensitive, but in either case there must be no interference between materials in the assay 
matrix and the optical properties of the analyte if a continuous assay is to be employed. That is, 
the optimal wavelengths of excitation or emission must not be absorbed or emitted by other 
materials in the assay matrix such as excess substrate. In the case of prodrugs or PET imaging 
agents that are potential substrate-based probes of specific enzymes, the drugs or reporter 
groups are not chosen based on their optical properties but rather their biologically properties. 
As a result, there are cases where a stopped assay in combination with techniques other than 
spectrophotometry must be employed for the detection of reporter groups. 
 Since the quinoline reporter groups employed in our probe candidates do not have 
suitable optical properties for detection by means of a continuous assay, a convenient end-
point assay was established, employing high-performance liquid chromatography (HPLC) in the 
resolution and detection of the quinoline reporter groups. In addition, poor solubility of probe 
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candidates was noted prior to achieving enzyme-saturating concentrations of substrate and 
therefore a value of kcat/KM could not be derived from full Michaelis-Menten curves. As a result, 
a commonly used mathematical estimation of kcat/KM using low substrate concentrations was 
employed, based on an alternative representation of the Michaelis-Menten equation. 
 The Michaelis-Menten model of enzyme kinetics describes substrate binding and 
catalysis in terms of reaction rate constants as seen in Scheme 5. 
 
Scheme 5: General scheme for Michaelis-Menten Kinetics 
 
 Where k1 and k-1 are equilibrium constants representing the rate of formation of the 
enzyme-substrate complex [ES] for a given substrate S, and k2 represents the rate of catalysis 
(or kcat) to product P. The effective rate of hydrolysis is represented by the following 
relationship: 
 
    
   
      
     
Equation 1 
 
 Where v0 represents the initial rate of hydrolysis, the term [S]/(KM + [S]) represents the 
ratio of enzyme bound to ligand, and Vmax represents the maximum velocity under saturating 
concentrations of substrate. As seen in a Michaelis-Menten plot (Figure 8), KM represents the 
concentration of substrate at which half of the maximal velocity Vmax is achieved. The equation 
demonstrates that v0 is proportional to [S] at low concentrations of substrate, noted by the 
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linear portion of the plot. However upon saturating concentrations of substrate, when [S] >> 
KM, v0 ≈ Vmax and the velocity is independent of substrate concentration as observed by the 
plateau. The kcat term of kcat/KM is derived from such a plot by dividing Vmax by total enzyme 
concentration ([E]total = [ES] + [E]). 
 
 
Figure 8: Michaelis-Menten curve. The initial rate of reaction v0 is represented along the y-axis while 
substrate concentration [S] is represented along the x-axis. KM represents the substrate concentration at 
which half the maximal velocity Vmax is achieved, and the two values are used to elucidate a kcat/KM value 
for a given substrate and enzyme. 
 
 When saturating concentrations of substrate cannot be achieved due to solubility, 
availability, time, or cost of precious substrates, the linear portion of the curve at low [S] can be 
used to estimate the combined kcat/KM term
8-12. By substituting Vmax = k2[E]total = kcat[E]total into 
Equation 1, the following is obtained: 
 
    
               






When [S] << KM as represented by the linear portion of a Michaelis-Menten curve, 
 
    








        
    
  




 Equation 3 represents a second order rate equation with units µM-1Sec-1 and is 
rearranged to provide Equation 4. In this representation of the Michaelis-Menten equation, 
v0/[S] represents the slope of the linear fit while [E]total represents the enzyme concentration 
used for the assay. In other words, by dividing the slope of the linear fit v0/[S] by enzyme 
concentration, an estimation of kcat/KM can theoretically be obtained. Not only is this a useful 
method when encountering solubility issues at relatively high [S], it also proved to be valuable 
in streamlining the process of screening probes candidates using automated HPLC. Specific 
procedural details are provided in the following manuscript, and the resulting kinetic studies for 
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 Members of the cathepsin family of cysteine proteases are gaining interest as potential 
imaging biomarkers and drug targets due to their multifunctional roles in regulatory processes 
such as cell recycling and wound healing, but also due to their multifunctional roles in diseases 
such as cancer, asthma and arthritis. Developing imaging agents with the ability to assess 
cathepsin activity in vivo is important for identifying specific roles in disease and ultimately 
guiding therapy and drug development. We report here novel prodrug-inspired substrates that 
release lysosomotropic reporter groups upon activation by CTB and CTL. We hypothesize that 
aminoquinolines may be retained in the lysosome where the majority of cysteine cathepsins 
are primarily active. To evaluate this approach we first synthesized a variety of substrates 
bearing various aminoquinoline isomers connected to CTL and CTB recognition peptides 
derivatized with the prodrug linker p-aminobenzyl alcohol. Then, a convenient HPLC method 
was developed to estimate kcat/KM values first using commercial fluorogenic substrates then 
using the novel quinoline-modified probe candidates. Three of the candidates were hydrolyzed 
by CTL with very efficient kcat/KM values, suggesting that prodrug-inspired probes bearing AMQ 
reporters could potentially be adapted into PET imaging agents that are efficient substrates of 









 The cysteine cathepsins have various roles in healthy cell function, but their aberrant 
expression has been linked to aggressive cancer, arthritis, and various respiratory and 
lysosomal storage diseases1,2. There are 11 human cysteine cathepsins and interest has grown 
in cathepsins as biomarkers of disease or drug targets3. Most cysteine cathepsins are 
ubiquitously expressed, but by virtue of being involved in many normal and disease processes, 
their in vivo expression and activity varies greatly. The majority of cysteine cathepsins are found 
secluded in lysosomes and to a lesser extent endosomes, and therefore a reducing, acidic 
environment is needed for optimal activity. However in addition to the physiochemical 
environment and localization, catalytic activity is controlled by interaction with a complex 
system of other biological molecules. To begin, cathepsins are synthesized as mainly inactive 
proenzymes, and activation to their respectively mature counterparts can be carried out by the 
residually active proenzymes themselves, known as autocatalysis, or by other proteases 
operating in the lysosome. Inhibition of activity to prevent unwanted proteolysis can be 
controlled by diverse reversible small protein inhibitors called cystatins, thyropins, and serpins1. 
Variability in expression, proenzyme activation, and endogenous inhibition results in great 
variation in the catalytic activity of the cathepsins dependent on location in tissues and cells. 
Techniques which can assess the functional activity of cathepsins as opposed to expression 




 The increased expression and activity of cathepsins in various cancers, in combination 
with their involvement in various stages of tumor progression, has led to interest in cathepsins 
as imaging biomarkers and drug targets3. Overexpression and localization at the invading edge 
of a tumor or in the tumor microenvironment is linked with aggressive cancers4, while 
intracellular CTB has been shown to indirectly induce apoptosis in tumor cells5. CTB has also 
been reported to not only blunt tumor response to chemotherapy, but actually promote tumor 
growth in response to chemotherapy6,7. Although there is evidence suggesting that CTB has 
important roles in cancer and its prognosis, probes capable of evaluating CTB activity in vivo are 
needed to specifically define these roles and determine if CTB is a legitimate biomarker of 
aggressive cancer or a potential therapeutic target. 
 The first reported strategy for visualizing cysteine protease activity in cells and animals 
originated with Bogyo and coworkers, who developed fluorescently quenched activity-based 
probes (qABPs) employing an acyloxymethyl ketone (AOMK) warhead8. The AOMK warhead, 
which is conjugated to a fluorophore-derivatized dipeptide, alkylates the active site cysteine 
residue to form a covalent thioether ketone linkage. Although efficient at visualizing cathepsin 
activity in vitro, the qABPs lacked specificity as both CTB and CTL were efficiently labelled. And 
while these smart ABPs yield a fluorescent signal only upon reacting with and attaching to the 
cysteine active site, a potential drawback results from the 1:1 stoichiometry, limiting signal 
accumulation and image contrast. 
 To improve signal contrast by exploiting the catalytic power of the cysteine proteases, 
Kim and coworkers designed substrate-based probes (SBPs) using a polymer composed of 
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monomers conjugated to either a tumor-targeting hormone or a CTB-targeting substrate in an 
alternating fashion. Each cathepsin-targeting peptide was derivatized with a Cy5.5 fluorophore 
and the BHQ-3 quencher at opposite termini of the CTB-hydrolyzable bond, allowing the 
fluorophore to be released to yield strong fluorescence in correlation with CTB activity. 
Although SBPs may increase contrast since a single enzyme can hydrolyze and release 
thousands of probe molecules per minute, nanoparticles typically have poor cell permeability 
and long circulation times meaning that images can often only be taken days after injection. In 
addition, nanoparticle imaging probes depend heavily on the enhanced permeability and 
retention (EPR) of tumor vasculature for tumor delivery. However heterogeneity of the EPR 
effect within and between tumor types has hampered the development and utility of imaging 
agents and drugs employing a nanoparticle design. In contrast, small molecule substrate-based 
probes could potentially offer better pharmacokinetic properties while still offering a 
mechanism for signal amplification. 
 Although SBPs offer the advantage of signal amplification, a major drawback commonly 
encountered is the rapid diffusion of the reporter molecules from the site of enzyme activation. 
However cathepsins are primarily active in the acidic lysosome of cells, and a low pH may 
potentially be used to enhance the retention of reporter groups within this environment by 
using basic amines that become protonated and membrane impermeable once enzymatically 
released. Not long after discovering the lysosome six decades ago, deDuve reported that 
weakly basic amines spontaneously accumulate to high concentrations after becoming ionically 
charged in the acidic environment of the lysosomes, a phenomenon called lysosomotropism9. 
Indeed, there are examples of imaging agents and therapeutics that have taken advantage of 
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lysosomotropic properties for increased sensitivity or selectivity toward their given targets.  
Lysosomal trapping as a mechanism of signal amplification in PET was demonstrated by Hall and 
coworkers, who established that [11C]N-desmethyl-loperamide enters brains cells and 
accumulates in lysosomes therein10. Lysosomotropic anticancer agents have been shown to 
promote cancer cell selectivity at least in vitro11, and a number of investigators have reported 
on the effects of lysosomotropism on drug biodistribution in tissue12. Although a 
lysosomotropic epoxide-based inhibitory cathepsin probe was reported by Wright and 
coworkers13, the design causes it to be retained in the lysosome regardless of cathepsin 
recognition. Since most cysteine proteases reside primarily in the lysosome, SBPs that employ 
lysosomotropic amines would have the advantages of rapid turnover while trapping the 
reporter in the lysosome. 
 We report here the synthesis and in vitro kinetic analysis of eight novel three-
component SBPs consisting of a dipeptide substrate, a prodrug linker, and one of four 
aminoquinoline reporter groups. Three of the four quinoline reporter groups used (3-AMQ, 4-
AMQ and 5-AIQ) have previously been reported as lysosomotropic14 but have yet to be used as 
reporter groups of enzymatic activity. All probes were easily prepared and through a 
convenient HPLC method shown to be efficiently hydrolyzed by cathepsins B and L. Importantly, 
three of the eight probes were very efficiently hydrolyzed by CTL and are therefore excellent 
lead compounds for the design of future PET imaging probes. This work is a significant step 
toward the development of substrate-based probes that provide an amplification of signal 




4.3: Results and discussion 
 
4.3.1: Probe Design 
 
 
 Rather than functioning as activity-based inactivators that are covalently retained in the 
active site of the target, we desired substrate-based probes that would be catalytically 
processed by CTB or CTL to release a lysosomotropic reporter molecule where cysteine 
cathepsins primarily reside. We hypothesize that our substrate-based approach will take 
advantage of the catalytic power of the target protease while still locking the reporter molecule 
at the site of hydrolysis, thus providing an amplification of signal compared to an activity-based 
approach which inactivates the target enzyme. Designed to be efficient substrates for CTB and 
CTL, these prodrug-inspired peptidic probe candidates employ a three-component design 
consisting of a dipeptide substrate that provides high affinity and specificity to CTB and/or CTL, 
a self-immolative linker that spontaneously releases a reporter upon its enzymatic hydrolysis 
from the peptide, and one of various aminoquinoline reporters that are expected to be locally 
retained in the cathepsin-laced lysosome. Analogous to prodrugs that are processed to release 
an active drug as seen in Figure 9, these substrate-based probes are designed to be efficiently 
hydrolyzed by CTB to release one of various aminoquinoline isomers that should be retained 
within the lysosome. The PABA linker has been used in the design of prodrugs, and until 
recognition and cleavage by CTB within the lysosome of the cell, the intact probe should be cell 
permeable and travel throughout the body to reach the target site. 18F-labelled lysosomotropic 
reporter groups could prove useful toward developing cathepsin substrate-based PET agents 




Figure 9: Prodrug-inspired substrate based approach for CTB and CTL probes. Prodrugs are 
enzymatically processed at a target site to release an active drug. In an analogous fashion, the prodrug-
inspired probe candidates employed herein are efficiently hydrolyzed by CTB and CTL to release one of 
various aminoquinoline isomers, which are all expected to accumulate in the cathepsin-occupied 
lysosome and can foreseeably be 18F-radiolabeled. Such substrate-based probes offer an amplification of 




 To evaluate lysosomotropic amines in the context of potential PET imaging reporter 
molecules for lysosomal enzymes, we first synthesized substrates that are likely to be rapidly 
hydrolyzed by several cysteine cathepsins. The majority of cysteine cathepsins prefer a 
positively charged species in the P1 position of the peptide substrate and a hydrophobic species 
in the P2 position
15. We therefore synthesized derivatives employing (s)-lysine and (s)-
phenylalanine at the P1 and P2 positions respectively (Figure 10), while protected at the N-
terminus using carboxybenzyl (Z) as this has been shown in literature to be well accepted by the 
P3 pocket of many cysteine cathepsins. However, we also desired probes that had selectivity to 
CTB over other cysteine cathepsins. CTB is unique in that it can accept a positively charged 
amino acid at the top of its P2 pocket. This is due to the presence of a glutamic acid residue at 
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the top of the P2 pocket. To take advantage of this substrate preference, we synthesized probe 
candidates with lysine as the amino acid in both the P1 and P2 positions. 
 
Figure 10: The general structure of the novel prodrug-inspired probe candidates reported herein. At 
the P1 and P3 positions of the peptidic probe candidates are lysine and carboxybenzyl respectively, both 
shown to be well accepted by the S1 and S3 subsites of the enzyme. At the P2 position is either 
phenylalanine, known to be well-tolerated by most cathepsins, or lysine, hopefully exploiting the unique 
ability of CTB to accept positively charged groups within the S2 site. The PABA linker conjugates the 
dipeptides to one of various aminoquinolines (3-AMQ, 4-AMQ, 5-AIQ, or 6-AMQ). 
 
 There are several advantages of incorporating the prodrug-inspired PABA linker into 
three-component probe candidates for CTB. The prodrug inspired PABA linker enables the 
conjugation of the aniline based aminoquinoline reporters through a chemically and 
metabolically stable carbamate linkage. Without PABA, a peptide directly derivatized with an 
aminoquinoline reporter would form a reactive amide that is likely to be processed by a 
number of proteases or esterase enzymes. Furthermore, PABA can extend into the active cleft 
of CTB, preserving recognition when bulky substituents such as drugs or contrast agents are 
placed at the P2' position. Indeed, prodrugs employing PABA as a self-immolative linker have 
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not only been shown to be efficiently processed by cathepsins to release an active drug, but are 
serum stable as well. 
 The four quinoline reporter groups employed in our prodrug substrates are 3-
aminoquinoline (3-AMQ), 4-aminoquinoline (4-AMQ), 5-aminoisoquinoline (5-AIQ), and 6-
aminoquinoline (6-AMQ), as shown in Figure 11. The approximate pH range of the lysosome is 4 
- 516, while the quinoline isomers 3-AMQ, 4-AMQ, 5-AIQ, and 6-AMQ have pKa values of 5.0, 
9.2, 6.0 and 5.6 respectively14,17. These quinolines are thus expected to be mostly ionic and 
retained in the acidic lysosome where CTB and CTL primarily reside. The lysosomotropic 
properties of 3-AMQ, 4-AMQ, and 5-AIQ have been reported as the ratio of 
[lysosomal]/[cytosolic] accumulation, with 4-AMQ having a value of approximately 60, while 
that for 5-AIQ and 3-AMQ was approximately 25 and 4 respectively14. The pKa values of the 
individual quinolines correlate with lysosomotropic results and likely determine the degree to 
which each becomes retained in the low pH of the lysosome. Although 6-AMQ is not reported 
in literature as being lysosomotropic, its pKa of 5.6 means it is also likely to be charged and 
retained within the lysosome. It is important to acknowledge that the ratio of lysosomal to 
cytosolic accumulation was obtained by treating live cells with each aminoquinoline isomer. In 
such a case, each quinoline must cross several lipid bilayers in contrast to being released 
directly into the acidic lysosome by the cysteine cathepsin enzyme. Therefore, lysosomal 
retention of an enzymatically released aminoquinoline may differ from lysosomal accumulation 
in cells treated with each quinoline. In order to first assess the potential utility of cysteine 
cathepsin SBPs bearing lysosomotropic reporters groups, we synthesized a series of eight probe 
62 
 
candidates bearing aminoquinoline isomers as reporters and determined the kcat/KM values of 
each using recombinant CTB and CTL. 
 
Figure 11: The four quinoline isomers used as reporter groups in our substrate-based probes. For the 
purpose of assessing the ability to image cathepsins using lysosomotropic reporter groups, amines with 
varying pKa were chosen which can all be conjugated to our substrates via similar chemistry.  3-AMQ, 4-
AMQ, and 5-AIQ have been reported as being lysosomotropic when incubated with cells, and because 6-





 In order to evaluate the suitability of lysosomotropic amines as reporter molecules of 
substrate-based molecular probes, we first sought a convenient route for their preparation. To 
begin, the two substrate-linker peptides Z-Phe-Lys(BOC)-PAB-OH and Z-Lys(BOC)-Lys(BOC)-PAB-
OH were prepared using well-established peptide chemistry as seen in Scheme 618. 
Incorporation of the 3-AMQ, 4-AMQ, 5-AIQ, and 6-AMQ reporter groups by means of a 
carbamate linkage was carried out by reacting their respective isocyanoquinolines with the 
acidic hydroxyl group of PAB-OH as seen in Scheme 7. 3-AMQ, 5-AIQ, and 6-AMQ are all 
converted to their respective isocyanates by means of phosgenation in the presence of either 
TEA or DMAP. 4-quinolinecarboxylic acid (4-QCA) was converted to its respective isocyanate 
through a Lossen Rearrangement using CDI and hydroxyl amine19, so as to be incorporated as 
the 4-AMQ reporter group. We chose 4-QCA as it is commercially inexpensive relative to its 4-
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AMQ counterpart and is conveniently coupled to PABA using a Lossen Rearrangement in a one-
pot procedure. Isocyanation and subsequent coupling of 3-AMQ and 6-AMQ to Z-FK-PABA and 
Z-KK-PABA was achieved within 6 hours while 4-AMQ and 5-AIQ were coupled overnight. All 
BOC-protected carbamates 5a-d and 6a-d were deprotected quantitatively or in high yield using 
50% TFA:CH2Cl2, providing the final probes 7a-d and 8a-d. 
 
 
Scheme 6: Formation of precursor peptides 3 and 4. (a) Z-Phe-OSu, NaHCO3, THF-H2O, rt, 16h; (b) Z-Lys-
OSu, Et3N, DMF, 0°C to rt, 16 h; (c) PABA, THF, EEDQ, rt, 16 h 
 
 
Scheme 7: General scheme for conjugation of the quinoline reporters to the peptide precursors 3 and 






Table 1: Structures and yields for the deprotected probe candidates. Yields are based on starting 
peptides 3 and 4. 
 
4.3.3: Enzymatic Assays 
 
 
 Enzyme kinetic studies are ideally performed using chromogenic or fluorogenic 
substrates, where continuous turnover of substrate is conveniently quantified using 
spectrophotometry. However, continuous plate reader assays cannot always be used due to 
high concentrations of substrate interfering with the optical wavelengths of the reporter. 
Although the optical properties of the aminoquinoline reporters are not suitable for detection 
using a continuous plate reader assay, we show that 3-AMQ, 4-AMQ, and 6-AMQ have strong 
fluorescence when resolved and detected using HPLC. While 5AIQ was not fluorescent under 
any conditions, it has strong UV absorbance. Therefore, kcat/KM values can be estimated using a 
convenient stopped HPLC method monitoring the release of aminoquinolines. In addition, poor 
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solubility of probe candidates was noted prior to achieving enzyme-saturating concentrations 
of substrate and therefore values of kcat/KM could not be derived from full Michaelis-Menten 
curves. To estimate kcat/KM values, the slope of the linear fit of v0 vs [S] at low substrate 
concentrations was fitted to the linear relationship of [vo/(S)]/[E] = kcat/KM
20-24. In this 
representation of the Michaelis-Menten equation, v0/S represents the slope of the linear fit 
while [E] represents the final enzyme concentration. 
 In order to verify that kcat/KM values of our probe candidates can be accurately predicted 
using HPLC and this representation of the Michaelis-Menten equation, benchmark kinetic 
values for two commercial substrates were determined using a continuous assay and compared 
to values obtained using the stopped HPLC method. Enzymatic turnover was stopped at known 
times using sodium chloroacetate, a potent inhibitor of cysteine proteases. This is a shelf-
stable, inexpensive water-soluble inhibitor which alkylates all cysteine active sites immediately. 
Although CTB and CTL were never assayed at concentrations exceeding 3 nM, sodium 
chloroacetate was used in 50 mM excess. This ensured saturation and complete inactivation 
while still maintaining solubility of the stopped solutions. 8-aminoquinoline was conveniently 
included in the stopping solution as the HPLC internal standard for all assays. The efficacy of the 
stopping method was confirmed using plate reader assays of Z-RR-AMC and Z-FR-AMC, noting 
instantaneous inactivation of each enzyme. 
 As shown in Figures 12 and 13, kcat/KM values can be accurately estimated for 
commercial substrates Z-RR-AMC and Z-FR-AMC as substrates for CTB and CTL respectively. To 
ensure data points were within the linear range of the Michaelis-Menten curve, a four-fold 
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substrate concentration range was used to provide R2 values of at least 0.95 in all cases. To 
ensure that v0 was accurately measured up to the 10 minute stopping point, the wells 
containing the lowest substrate concentration were stopped after 20 and 30 minutes and were 
shown to be within the linear portion of the reaction. Not only is this a useful method when 
encountering solubility issues at relatively high [S], but it also proved to be valuable in 
streamlining the process of screening probe candidates using HPLC. Once we were confident 
that the kcat/KM values obtained via HPLC was consistent with plate reader data using the 








Figure 12: Comparative results of the CTB plate reader assay and HPLC estimation. The similar kcat/KM 
values obtained in all cases indicate that an HPLC-quantified stopped assay can be used to estimate the 












Figure 13: Comparative results of the CTL plate reader assay and HPLC estimation. The similar kcat/KM 
values obtained in all cases indicate that an HPLC-quantified stopped assay can be used to estimate the 
catalytic efficiency of CTL for a given substrate. 
 
 For convenience and consistency in screening the quinoline probe candidates, a 
standardized HPLC elution method was desired for resolving all of the quinolines from other 
assay materials including substrate, buffer and internal standard. The standardized HPLC 
elution method that is used in all cases is also in unison with the optimal optical conditions of 
the quinoline reporter groups. While 3-AMQ, 4-AMQ, and 5-AIQ have yet to be used as reporter 
groups of enzymatic activity, 6-AMQ has been employed as a reporter of hydrolase activity. The 
wavelengths of maximum excitation and emission for unconjugated 6-AMQ have previously 
been shown to be unaffected by pH, however the resulting fluorescence intensity is optimal in 
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acidic conditions. We therefore employed 0.1% TFA (pH < 2) as a solvent system to improve 
peak separation and resolution, fortuitously increasing the fluorescent yield of 6-AMQ. 
Surprisingly, 3-AMQ and 4-AMQ were also optimally fluorescent when resolved under the same 
HPLC conditions and 5-AIQ showed strong absorbance in the UV range. In order of increasing 
fluorescence intensity, 6-AMQ, 4-AMQ, and 3-AMQ all proved to be highly sensitive reporters 
by means of HPLC. All quinolines are eluted and detected within 9 minute retention times and 
virtually no baseline noise is observed on either the VWD or FLD. 
 We proceeded to verify that the PABA linker does not influence the release rate of 
reaction products from the active sites of CTB and CTL prior to kinetic studies. Due to the 
varying pKa of the quinolines used herein, it was necessary to assess how PABA affects the 
release of aminoquinolines following hydrolysis of the substrate. To demonstrate that 
enzymatic hydrolysis of each substrate was a slower kinetic process than PABA decomposition 
and AMQ release, we demonstrated that the initial rate of hydrolysis was proportional to a 10 













Figure 14: Linear relationship between Cathepsin concentration and initial velocity of commercial and 
quinoline substrates. All substrates were assayed at 40µM, Z-RR-AMC and Z-FR-AMC were assayed 
using the continuous plate reader method, while the quinoline-derived substrates were assayed using 
the HPLC method. The linearity in all cases suggests that the release of product is faster than enzymatic 
hydrolysis of substrate. 
 
 The slope of the linear fit v0/[S]  is shown for each probe candidate in Figures 15, 16 and 
17 for CTB and CTL, used to estimate kcat/KM using the same HPLC method as used for the 
commercial fluorogenic substrates. As seen in Table 2, the aminoquinoline-based probes are 
efficient substrates of CTB and CTL, however CTL hydrolysis suffered drastically with the use of 
the Z-KK-PABA-AQ probes.  Interestingly, CTL has significantly higher kcat/KM values for the Z-FK-
PABA-AQ probes than does CTB. This is not surprising as CTL is considered a more potent 





Figure 15: Linear fits of v0/[S] used in the estimation of kcat/KM for the quinoline probes when assayed 
with CTB. CTB was assayed at 0.3 nM and the resulting kcat/KM for 7a, 8a, 7b, 8b, 7c, 8c, 7d, and 8d are 
36 ± 1, 82 ± 2, 128 ± 4, 123 ± 3, 89 ± 4, 72 ± 1, 56 ± 1, and 62 ± 2 sec-1mM-1 respectively. 
 
 
Figure 16: Linear fits of v0/[S] used in the estimation of kcat/KM for the Z-FK quinoline probes when 
assayed with CTL. CTL was assayed at 0.005 nM and the resulting kcat/KM for 7a, 7b, and 7d are 9.4 × 10
3 








Figure 17: Linear fits of v0/[S] used in the estimation of kcat/KM for the Z-KK quinoline probes when 
assayed with CTL. CTL was assayed at 3.0 nM and the resulting kcat/KM for 8a, 8c, and 8d are 37 ± 1, 31 ± 
1, and 20 ± 1 sec-1mM-1 respectively. 
 
 The high kcat/KM values of hydrolysis for Z-FK-PABA-AQ probe candidates by CTL are 
particularly interesting. While the stopped assay allows us to obtain estimations for kcat/KM, it 
does not allow us to determine the individual kcat and KM. For example, high kcat/KM values can 
result from an exceptionally low KM or high kcat value. However we can obtain insight into the 
KM value by considering the substrate and enzyme concentrations used in each assay. All assays 
of quinoline-based probes involving CTB employed a substrate concentration range of 10-40 
µM, as did CTL for the Z-KK-PABA-AQ probes. The Z-FK-PABA-AQ probes however were 
saturating CTL at all initial concentrations employed, requiring lower concentrations of 
substrate in the nM range (0.25-1 µM). Since KM is the concentration of substrate required to 
reach 1/2Vmax and nM concentrations of Z-FK-PABA-AQ substrates were required to avoid 
maximal velocity of CTL, the KM values in these cases must be very low. Therefore, affinity of 
the Z-FK-PABA-AQ probes to the active site of CTL was high. Furthermore, a very low enzyme 
concentration of 0.005 nM was used compared to the 0.3 nM and 3.0 nM used in the other CTB 
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and CTL assays in order to stay within 10% turnover of substrate. This indicates that not only do 
the Z-FK-PABA-AQ probes have a low KM value for CTL, but they are turned over rapidly as well 
with a high kcat value, leading to the extraordinarily high kcat/KM values observed. 
 
 















 We synthesized a series of substrate-based probes, and using a convenient HPLC 
method, four different aminoquinoline isomers have been evaluated as reporters for CTB and 
CTL activity. Although the Z-FK-based peptides were efficient substrates of CTB, much higher 
kcat/KM values were measured for CTL. In contrast, Z-KK-based probes are efficient substrates of 
CTB and relatively poor substrates of CTL. This suggests that a prodrug inspired approach using 
lysosomotropic reporters may have utility for detecting cysteine cathepsin activity in vivo. 
Future work will involve cell assays to evaluate cell permeability and specificity to cysteine 
cathepsin enzymes, in addition to evaluating the subsequent retention of the various 


















Proton (1H) and carbon (13C) NMR spectra were acquired at the Lakehead University 
Instrumentation Laboratory (LUIL) on a Varian Unity Inova 500 MHz spectrometer and J 
(coupling constant) values are estimated in hertz (Hz). Thin layer chromatography (TLC) and 
silica gel column chromatography were performed using TLC silica gel 60 F254 (EMD) and 
SiliaFlashP60 (SiliCycle) respectively. Human Cathepsin B was purchased from Novoprotein 
(Cat# C398, Accession# P07858), as was Cathepsin L (Cat# C401, Accession# P07711). 
Continuous kinetic studies were performed in a Biotek Synergy 4 plate reader. HPLC was 
performed on an Agilent 1200 Infinity LC with stopped reactions separated on an Agilent Eclipse 
XDB-C18 column (4.6 mm, 150 mm, 5 µm) and detected using a 1200 series variable 
wavelength detector (G1314B). 
 
 
Enzyme Kinetic Studies 
 
The reaction mixture (300 µL final volume) consisted of 30 mM acetate-NaOH, pH 5.5, 3.0 mM 
EDTA, 2.0 mM DTT, and 10% DMSO. CTB was assayed at a final concentration of 0.3 nM in all 
cases. When assaying CTL with the commercial substrate Z-FR-AMC, a final enzyme 
concentration of 0.3 nM was used. When assaying CTL with Z-FK based probe candidates a final 
enzyme concentration of 0.005 nM was used, while a final CTL enzyme concentration of 3.0 nM 
was used when assaying the Z-KK based probe candidates. Samples were prewarmed at 37°C 
for 15 min, and the reaction was initiated upon addition of the enzyme. For commercial 
substrates Z-RR-AMC and Z-FR-AMC, the activity was monitored spectrophotometrically for the 
release of 7-amino-4-methylcoumarin (AMC; excitation 380 nm; emission 460 nm). For novel 
probe candidates, reactions were stopped after 10 minutes by adding 100 µL of reaction 
mixture to 50 µL of stopping solution. Stopping solution was freshly prepared prior to each 
assay and consists of 50 mM sodium chloroacetate, 15% methanol, and approximately 50 µM 8-
aminoquinoline as internal standard. All stopped reactions were resolved on HPLC using 
acetonitrile (0.1% TFA) as organic solvent and H2O (0.1% TFA) as aqueous solvent. 3-AMQ and 
4-AMQ were both detected on the FLD using an excitation of 240 nm, the former having a 
maximum emission of 465 nm and the latter having a maximum emission of 355 nm. 6-AMQ 
was detected on the FLD using an excitation of 260 nm and a maximum emission of 530 nm. 5-












Compounds 3 and 4 were prepared according to literature18 
 
7a, 7d, 8a, and 8d. To a solution of either 6AMQ or 3AMQ (200 mg, 1.4 mmol) in DCM at ice bath 
temperature was added TEA (393 uL, 2.8 mmol) dropwise followed by dropwise addition of 15% 
phosgene in toluene (954 uL, 1.4 mmol). After continued stirring for 30 minutes at ice bath temperature 
the solution was allowed to reach room temperature, after which either 3 or 4 (0.7 mmol) was added as 
a solid. The mixture was brought to 50°C and DMF was then added dropwise until complete solubility 
was achieved, stirring for an addition 2 hours. The solution was brought to room temperature, and the 
solvents were removed under reduced pressure. Ethyl acetate is added and the solution is washed with 
0.1 M HCl, sat. NaHCO3, and sat. NaCl. Following removal of ethyl acetate under reduced pressure, the 
residue is purified by silica gel column chromatography using ethyl acetate as eluent to obtain the pure 
BOC-protected carbamates 5a, 5d, 6a, and 6d in yields of 64%, 24%, 20%, and 16% respectively based on 
starting peptides 3 and 4. The BOC-protected carbamates (50 mg) are all deprotected by stirring in 
trifluoroacetic acid-DCM (1:1 v/v, 5 mL) for 10 minutes, followed by addition of diethyl ether to form a 
precipitate which is centrifuged out of suspension, successively washed with diethyl ether and ethyl 
acetate, and dried under high vacuum to provide title compounds 7a, 7d, 8a, and 8d in yields of 64%, 
24%, 20%, and 13% respectively based on precursor peptides 3 and 4. That is, deprotection was 
quantitative in all cases except in furnishing 8d, which was obtained with a yield of 82% from the BOC 
protected counterpart 6d. 
 
7b and 8b. To a solution of 4-QCA (120 mg, 0.6 mmol) in ACN (25 mL) is added CDI (120 mg, 0.7 mmol), 
the mixture stirred for 1 hour followed by addition of hydroxyl amine hydrochloride (55 mg, 0.7 mmol) 
and further stirring for 2 hours followed by a second addition of CDI (140 mg, 0.9 mmol). After stirring 
this mixture for 30 minutes, either 3 or 4 (0.3 mmol) is added and the reaction is stirred at 60°C for 16h. 
Solvents are removed, DCM is added, and the solution is washed with 0.1 M HCl, NaHCO3, and sat. NaCl. 
Following removal of DCM under reduced pressure, the residue is purified by silica gel column 
chromatography using ethyl acetate as eluent to obtain the pure BOC-protected carbamates 5b and 6b 
in yields of 27% and 19% respectively based on starting peptides 3 and 4. The BOC-protected 
carbamates (50 mg) are deprotected by stirring in trifluoroacetic acid-DCM (1:1 v/v, 5 mL) for 10 
minutes, followed by addition of diethyl ether to form a precipitate which is centrifuged out of 
suspension, successively washed with diethyl ether and ethyl acetate, and dried under high vacuum to 
provide title compounds 7b and 8b in yields of 27% and 17% respectively based on precursor peptides 3 
and 4. That is, BOC-protected carbamate 5b was quantitatively deprotected while 8b was obtained with 




7c and 8c. To DCM (30mL) at ice bath temperature  is added 15% phosgene in toluene (2.6 mL, 3.9 
mmol) dropwise, followed by DMAP (1 g, 8.2 mmol) in DCM (10mL), and 5AIQ (500 mg, 3.5 mmol) in 
DCM (10 mL). The mixture is stirred at room temperature for 16 h, dried under reduced pressure, and 
the isocyanate is extracted using ether before filtering. Either 3 or 4 (0.4-0.5 mmol) is added in THF 
(10mL) to the ether solution, stirring for an additional 2 hours. After removing volatiles under reduced 
pressure, ethyl acetate was added and the crude product was washed using 0.1 M HCl, sat. NaHCO3, and 
sat. NaCl. Following removal of ethyl acetate under reduced pressure, the residue is purified by silica gel 
column chromatography using ethyl acetate as eluent to obtain the pure BOC-protected carbamates 5c 
and 6c in yields of 34% and 21% based on starting peptides 3 and 4. The BOC-protected carbamates (50 
mg) are deprotected by stirring in trifluoroacetic acid-DCM (1:1 v/v, 5 mL) for 10 minutes, followed by 
addition of diethyl ether to form a precipitate which is centrifuged out of suspension, successively 
washed with diethyl ether and ethyl acetate, and dried under high vacuum to provide title compounds 
7c and 8c in yields of 34% and 21% respectively based on precursor peptides 3 and 4. That is, both BOC 
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Cbz-Phe-Lys(BOC)-PABA-3AMQ: 1H NMR (500 MHz, DMSO): δ 8.88 (bs, 1H), 8.48 (s, 1H), 8.33 
(s, 1H), 7.92 (dd, J = 8.2, 20.3 Hz, 2H), 7.53-7.70 (m, 4H), 7.42 (bs, 3H), 7.15-7.37 (m, 11H), 5.18 
(s, 2H), 4.96 (s, 2H), 4.38-4.45 (m, 1H), 4.30-4.37 (m, 1H), 4.08 (s, 1H), 3.34 (bs, 1H), 2.98-3.10 
(m, 1H), 2.83-2.95 (m, 2H), 2.75 (t, J = 12.5 Hz, 1H), 1.70-1.80 (m, 1H), 1.60-1.70 (m, 1H), 1.34 (s, 
9H), 1.20-1.46 (m, 4H); 13C NMR (125 MHz, DMSO): δ 172.07, 171.17, 156.32, 156.02, 154.19, 
144.54, 144.33, 139.41, 138.55, 137.49, 133.48, 131.55, 129.71, 129.55, 129.03, 128.75, 128.69, 
128.68, 128.67, 128.66, 128.47, 128.37, 128.13, 127.95, 127.89, 127.55, 126.69, 120.93, 120.91, 
120.89, 119.63, 105.00, 77.78, 66.48, 65.67, 56.57, 54.06, 37.88, 32.40, 29.74, 28.72, 23.25 
 
Cbz-Phe-Lys(BOC)-PABA-4AMQ: 1H NMR (500 MHz, CDCl3): δ 8.81 (d, J = 5.1 Hz, 1H), 8.69 (bs, 
1H), 8.08-8.13 (m, 2H), 7.83 (d, J = 8.4 Hz, 1H), 7.68-7.72 (m, 2H), 7.58-7.63 (m, 2H), 7.51-7.55 
(m, 1H), 7.10-7.40 (m, 13H), 5.23 (s, 2H), 5.06 (bs, 2H), 4.66-4.74 (m, 1H), 4.43-4.53 (m, 2H), 
2.99-3.16 (m, 5H), 1.65-1.80 (m, 1H), 1.53-1.65 (m, 1H), 1.42 (s, 9H), 1.38-1.48 (m, 4H); 13C NMR 
(125 MHz, DMSO): δ 172.07, 171.12, 156.33, 156.02, 154.27, 151.18, 149.04, 142.55, 139.37, 
138.51, 137.48, 131.46, 129.89, 129.68, 129.66, 129.58, 129.55, 128.75, 128.73, 128.49, 128.14, 
127.89, 126.70, 126.23, 122.89, 120.98, 119.64, 110.89, 77.79, 66.76, 65.68, 65.66, 56.51, 
53.96, 49.08, 32.43, 29.78, 29.76, 28.75, 28.72, 28.68, 23.24 
 
Cbz-Phe-Lys(BOC)-PABA-5AIQ: 1H NMR (500 MHz, DMSO): δ 10.39 (m, 1H), 9.95 (s, 1H), 9.42 (s, 
1H), 8.36-8.58 (m, 2H), 7.96-8.14 (m, 3H), 7.66-7.77 (m, 3H), 7.50-7.63 (m, 1H), 7.13-7.46 (m, 
13H), 6.66-6.89 (m, 1H), 5.12-5.20 (2H), 4.93-4.97 (s, 2H), 4.39-4.46 (m, 1H), 4.29-4.36 (m, 1H), 
3.00-3.10 (m, 1H), 2.82-2.94 (m, 1H), 2.71-2.79 (m, 1H), 1.71-1.82 (m, 1H), 1.60-1.71 (m, 1H), 
1.34 (s, 9H), 1.26-1.44 (m, 4H);  13C NMR (125 MHz, DMSO): δ 172.04, 171.22, 156.31, 156.01, 
155.04, 151.99, 151.96, 139.43, 138.59, 137.49, 133.78, 131.66, 130.55, 129.75, 129.36, 129.02, 
128.75, 128.68, 128.67, 128.45, 128.34, 128.12, 127.88, 126.67, 125.37, 125.31, 125.30, 125.29, 








Cbz-Phe-Lys(BOC)-PABA-6AMQ: 1H NMR (500 MHz, CDCl3, drops of MeOD): δ 8.68-8.71 (m, 
1H), 8.11-8.19 (m, 1H), 7.94 (d, J = 9.2 Hz, 1H), 7.54-7.65 (m, 3H), 7.11-7.43 (m, 12H), 5.20 (s, 
2H), 5.00-5.09 (m, 2H), 4.40-4.47 (m, 2H), 4.06 (s, 4H), 3.34-3.37 (m, 1H), 2.91-3.15 (m, 4H), 
1.80-1.89 (m, 1H), 1.59-1.70 (m, 1H), 1.40 (s, 9H), 1.38-1.50 (m, 4H); 13C NMR (125 MHz, CDCl3, 
drops of MeOD): δ 161.33, 141.83, 140.32, 140.06, 133.08, 133.00, 132.86, 132.83, 132.81, 
132.79, 132.42, 132.36, 132.34, 132.33, 132.04, 131.74, 131.72, 130.84, 125.48125.47, 124.04, 
124.03, 124.01, 70.90, 70.89, 60.11, 60.10, 57.56, 53.11, 52.94, 52.79, 52.77, 52.60, 52.42, 
45.01, 42.07, 32.19, 32.16, 26.54, 26.53, 26.52, 24.88 
 
Cbz-Lys(BOC)-Lys(BOC)-PABA-3AMQ: 1H NMR (500 MHz, DMSO): δ 8.83 (d, J = 2.5 Hz, 2H), 8.52 
(s, 1H), 7.95 (d, J = 8.5 Hz, 1H), 7.83 (d, J = 8.1 HZ, 1H), 7.53-7.67 (m, 4H), 7.42 (d, J = 8.6 Hz, 3H), 
7.25-7.38 (m, 6H), 5.22 (s, 2H), 5.10 (s, 2H), 4.46-4.51 (m, 1H), 4.11-4.16 (m, 1H), 3.50 (dd, J = 
7.0, 14.0 Hz, 1H), 3.32-3.34 (m, 2H), 2.99-3.07 (m, 4H), 1.59-1.98 (m, 4H), 1.36-1.55 (m, 26H); 
13C NMR (125 MHz, DMSO): δ 172.53, 171.22, 156.48, 156.02, 156.01, 156.01, 156.00, 155.99, 
154.18, 144.54, 144.53, 144.52, 144.52, 144.32, 144.31, 139.42, 137.49, 133.49, 131.50, 129.53, 
129.52, 129.51, 129.03, 128.79, 128.76, 128.75, 128.37, 128.23, 128.14, 128.11, 128.08, 127.94, 
127.91, 127.89, 127.53, 127.51, 119.57, 119.55, 77.79, 77.77, 66.47, 66.46, 65.86, 65.85, 65.84, 
53.88, 45.00, 33.82, 32.31, 32.30, 32.06, 32.06, 25.81, 24.92, 23.32, 23.22 
 
Cbz-Lys(BOC)-Lys(BOC)-PABA-4AMQ: 1H NMR (500 MHz, CDCl3): δ 8.77-8.80 (m, 1H), 8.22-8.33 
(m, 1H), 8.01 (d, J = 9.1 Hz, 1H), 7.81-7.86 (m, 2H), 7.71 (d, J = 8.6 Hz, 2H), 7.55 (dd, J = 4.4, 8.4 
Hz, 2H), 7.50 (d, J = 8.5 Hz, 4H), 7.33-7.46 (m, 5H), 5.28 (s, 2H), 5.18 (s, 2H), 4.54-4.59 (m, 1H), 
4.19-4.25 (m, 1H), 3.58 (dd, J = 7.0, 14.1 Hz, 1H), 3.39-3.42 (m, 2H), 3.04-3.15 (m, 4H), 1.67-2.03 
(m, 4H), 1.42-1.62 (m, 26H); 13C NMR (125 MHz, CDCl3): δ 172.65, 170.03, 156.68, 156.66, 
156.25, 156.25, 153.09, 151.06, 148.72, 141.08, 138.44, 135.95, 131.12, 130.33, 129.45, 129.38, 
128.52, 128.40, 128.39, 128.37, 128.30, 128.26, 126.27, 120.08, 119.75, 119.54, 109.15, 67.39, 
67.35, 67.30, 65.86, 55.66, 53.84, 44.99, 39.98, 39.96, 39.22, 39.20, 31.19, 31.15, 31.11, 31.06, 








Cbz-Lys(BOC)-Lys(BOC)-PABA-5AIQ: 1H NMR (500 MHz, MeOD): δ 9.23 (s, 1H), 8.44 (bs, 1H), 
8.02 (bs, 1H), 7.89-7.97 (m, 2H), 7.61-7.71 (m, 3H), 7.25-7.48 (m, 9H), 5.22 (s, 2H), 5.11 (s, 2H), 
4.46-4.51 (m, 1H), 4.09-4.17 (m, 2H), 3.31-3.34 (m, 2H), 2.98-3.08 (m, 5H), 1.62-1.97 (m, 4H), 
1.33-1.55 (m, 26H); 13C NMR (125 MHz, MeOD): δ 173.75, 173.74, 171.12, 155.47, 152.04, 
141.41, 138.22, 136.73, 133.01, 132.35, 128.63, 128.09, 127.64, 127.48, 127.46, 127.43, 124.42, 
124.40, 119.87, 115.74, 78.46, 66.39, 55.28, 55.27, 53.90, 39.75, 39.74, 39.73, 39.59, 39.58, 
31.4131.40, 31.39, 31.37, 31.36, 31.35, 29.20, 29.18, 29.17, 29.16, 29.14, 29.13, 29.12, 29.11, 
22.82, 22.79, 22.76, 22.75, 14.06 
 
Cbz-Lys(BOC)-Lys(BOC)-PABA-6AMQ: 1H NMR (500 MHz, MeOD): δ 8.69-8.72 (m, 2H), 8.23 (d, J 
= 8.2 Hz, 2H), 8.16 (s, 2H), 7.93 (d, J = 9.1 Hz, 2H), 7.73-7.77 (m, 1H), 7.64 (d, J = 8.3 Hz, 2H), 
7.23-7.51 (m, 7H), 5.10 (s, 2H), 5.00 (s, 2H), 4.45-4.51 (m, 1H), 4.11-4.17 (m, 1H), 3.50 (dd, 7.0, 
14.1 Hz, 1H), 3.30-3.35 (m, 2H), 2.96-3.08 (m, 4H), 1.59-1.96 (m, 4H), 1.31-1.56 (m, 26H); 13C 
NMR (125 MHz, MeOD): δ 173.74, 171.12, 157.27, 157.26, 157.16, 157.14, 157.13, 154.25, 
148.09, 143.97, 138.18, 137.51, 136.71, 136.28, 132.39, 129.09, 128.56, 128.23, 128.10, 127.64, 
127.48, 123.02, 121.49, 119.86, 119.82, 113.79, 113.78, 113.77, 113.76, 113.75, 78.46, 66.39, 
66.0966.06, 55.28, 55.26, 55.23, 53.92, 39.75, 39.74, 39.73, 39.62, 39.59, 31.42, 31.41, 31.39, 
31.37, 29.20, 29.17, 29.16, 29.14, 29.13, 29.12, 22.82, 22.79, 22.78, 22.77, 22.74 
 
Cbz-Phe-Lys(TFA)-PABA-3AMQ: 1H NMR (500 MHz, DMSO): δ 10.27 (d, J = 28.5 Hz, 2H), 8.90 (s, 
2H), 8.50 (s, 1H), 8.37 (bs, 1H), 7.86-8.02 (m, 3H), 7.50-7.74 (m, 4H), 7.43 (bs, 2H), 7.14-7.37 (m, 
11H), 5.18 (s, 2H), 4.95 (s, 2H), 4.41-4.49 (m, 1H), 4.29-4.38 (m, 1H), 3.17 (s, 1H), 3.06 (d, J = 
12.9 Hz, 1H), 2.72-2.83 (m, 3H), 1.30-1.85 (m, 6H); 13C NMR (125 MHz, DMSO): δ 158.85, 
158.59, 156.35, 156.30, 154.19, 154.10, 144.20, 139.37, 139.26, 138.51, 137.46, 133.49, 133.37, 
131.61, 129.69, 129.52, 128.92, 128.75, 128.69, 128.69, 128.47, 128.37, 128.14, 128.03, 127.96, 









Cbz-Phe-Lys(TFA)-PABA-4AMQ: 1H NMR (500 MHz, MeOD): δ 8.89-8.93 (m, 2H), 8.71-8.74 (m, 
2H), 8.61-8.65 (m, 2H), 8.10-8.14 (m, 2H), 7.87-7.91 (m, 1H), 7.70 (d, J = 8.7 Hz, 2H), 7.52 (d, J = 
8.7 Hz, 3H), 7.11-7.36 (m, 11H), 5.37 (s, 2H), 5.05 (dd, J = 12.7, 21.0 Hz, 2H), 4.47-4.53 (m, 1H), 
4.38-4.43 (m, 1H), 3.13 (dd, J = 5.9, 13.7 Hz, 1H), 2.88-2.97 (m, 3H), 1.39-1.98 (m, 6H); 13C NMR 
(125 MHz, MeOD): δ 172.97, 170.59, 157.05, 153.12, 151.74, 144.47, 139.17, 138.55, 136.83, 
136.68, 134.11, 131.33, 129.20, 129.02128.93, 128.51, 128.14, 128.07, 127.60, 127.26, 126.42, 
122.71, 120.95, 119.95, 119.17, 107.49, 67.75, 66.26, 56.67, 53.55, 39.12, 37.40, 31.03, 26.68, 
22.31 
 
Cbz-Phe-Lys(TFA)-PABA-5AIQ: 1H NMR (500 MHz, DMSO): δ 10.49 (s, 1H), 10.08 (s, 1H), 9.61 (s, 
2H), 8.47-8.64 (m, 1H), 8.18-8.33 (m, 3H), 8.12 (bs, 2H), 7.83 (bs, 1H), 7.73 (bs, 2H), 7.09-7.59 
(m, 14H), 5.17 (s, 2H), 4.95 (s, 2H), 4.41-4.49 (m, 1H), 4.29-4.38 (m, 1H), 3.10 (d, J = 13.2 Hz, 
1H), 2.77 (bs, 3H), 1.28-1.87 (m, 6H); 13C NMR (125 MHz, DMSO): δ 172.15, 172.08, 171.16, 
171.14, 171.07, 156.34, 156.28, 155.03, 154.94, 150.58, 150.56, 150.54, 139.50, 139.39, 138.63, 
137.86, 137.85, 137.50, 134.07, 133.94, 131.56, 131.24, 129.83, 129.78, 129.38, 129.30, 128.76, 
128.45, 128.13, 127.87, 127.26, 127.24, 126.78, 126.74, 126.73, 126.70, 126.67, 125.79, 119.60, 
119.51, 118.42, 118.39, 118.37, 65.64, 65.39, 56.71, 54.06, 31.80, 31.77, 26.86, 26.81, 26.76, 
22.79, 15.65 
 
Cbz-Phe-Lys(TFA)-PABA-6AMQ: 1H NMR (500 MHz, MeOD): δ 8.93 (d, J = 5.1 Hz, 1H), 8.79 (d, J 
= 8.5 Hz, 1H), 8.43 (bs, 1H), 8.10 (d, J = 9.1 Hz, 2H), 7.99-8.03 (m, 2H), 7.84 (dd, J = 5.1, 8.5 Hz, 
2H), 7.62 (d, J = 8.5 Hz, 2H), 7.44 (d, J = 8.7 Hz, 3H), 7.10-7.35 (m, 11H), 5.24 (s, 2H), 5.04 (dd, J = 
12.5, 21.7 Hz, 2H), 4.47-4.52 (m, 1H), 4.39-4.45 (m, 1H), 3.13 (dd, J = 5.8, 13.9 Hz, 1H), 2.86-2.97 
(m, 3H), 1.38-1.97 (m, 6H); 13C NMR (125 MHz, MeOD): δ 173.59, 171.05, 161.46, 161.18, 
157.23, 154.24, 141.16, 141.13, 141.11, 138.21, 136.68, 133.73, 132.27, 129.52, 128.79, 128.71, 
128.67, 128.19, 128.11, 127.72, 127.68, 127.59, 127.40, 125.25, 125.21, 124.89, 124.88, 119.87, 
66.45, 66.41, 66.37, 65.51, 54.91, 53.65, 39.12, 39.06, 31.14, 31.08, 31.04, 26.71, 26.66, 26.63, 







Cbz-Lys(TFA)-Lys(TFA)-PABA-4AMQ: 1H NMR (500 MHz, MeOD): δ 8.92 (d, J = 6.7, 2H), 8.72 (d, 
J = 6.7 Hz, 3H), 8.63 (d, J = 8.7, 2H), 8.08-8.16 (m, 2H), 7.87-7.92 (m, 1H), 7.67 (d, J = 8.6 Hz, 2H), 
7.51 (d, J = 8.6 Hz, 3H), 7.27-7.40 (m, 6H), 5.36 (s, 2H), 5.07-5.17 (m, 2H), 4.50-4.60 (m, 1H), 
4.08-4.19 (m, 1H), 3.32-3.34 (m, 3H), 2.89-2.98 (m, 5H), 1.44-2.01 (m, 12H); 13C NMR (125 MHz, 
MeOD): δ 173.62, 161.75, 161.47, 157.25, 153.12, 151.73, 144.46, 139.17, 138.58, 136.68, 
134.12, 131.33, 129.20, 128.52, 128.11, 127.68, 127.41, 122.72, 120.96, 120.93, 119.86, 119.79, 
119.17, 107.48, 67.70, 66.37, 65.51, 54.94, 54.90, 53.64, 39.15, 39.12, 39.08, 39.05, 31.14, 
31.07, 31.02, 26.67, 26.63, 22.46, 22.43, 22.41, 22.38, 22.32, 22.31, 14.06, 13.07 
 
Cbz-Lys(TFA)-Lys(TFA)-PABA-5AIQ: 1H NMR (500 MHz, MeOD): δ 9.50 (bs, 2H), 8.51 (bs, 2H), 
8.19-8.28 (m, 2H), 8.11 (d, J = 8.3 Hz, 1H), 7.85 (t, J = 8.0 Hz, 3H), 7.64 (d, J = 8.4 Hz, 2H), 7.46 
(bs, 3H), 7.29-7.39 (m, 6H), 5.25 (s, 2H), 5.07-5.16 (m, 2H), 4.52-4.57 (m, 1H), 4.09-4.19 (m, 1H), 
3.37 (s, 2H), 2.88-2.97 (m, 4H), 1.46-2.00 (m, 12H); 13C NMR (125 MHz, MeOD): δ 173.53, 
171.02, 161.31, 157.22, 155.35, 150.13, 150.12, 138.16, 136.68, 133.63, 132.49, 128.95, 128.68, 
128.12, 127.70, 127.67, 127.49, 127.40, 125.47, 119.84, 117.78, 117.76, 66.51, 66.46, 66.36, 
65.51, 54.84, 53.55, 39.14, 39.06, 31.23, 31.05, 27.39, 26.70, 26.66, 22.44, 22.35 
 
Cbz-Lys(TFA)-Lys(TFA)-PABA-6AMQ: 1H NMR (500 MHz, MeOD): δ 8.93 (bs, 2H), 8.76 (d, J = 8.5 
Hz, 2H), 8.41 (bs, 2H), 8.10 (d, J = 9.1 Hz, 3H), 7.98-8.03 (m, 2H), 7.83 (dd, J = 5.1, 8.4 Hz, 1H), 
7.64 (d, J = 8.5 Hz, 2H), 7.44 (d, J = 8.6 Hz, 3H), 7.28-7.39 (m, 6H), 5.23 (s, 2H), 5.11 (dd, J = 12.5, 
18.2 Hz, 2H), 4.50-4.56 (m, 1H), 4.12-4.19 (m, 1H), 3.31-3.35 (m, 2H), 2.88-2.97 (m, 4H), 1.43-
2.01 (m, 12H); 13C NMR (125 MHz, MeOD): δ 173.59, 171.05, 161.68, 161.40, 157.23, 154.05, 
144.19, 142.50, 139.6, 138.16, 137.61, 137.60, 137.59, 137.58, 137.56, 136.68, 132.38, 129.91, 
128.60, 128.15, 128.11, 127.68, 127.39, 126.06, 123.53, 121.75, 119.87, 113.56, 66.37, 66.24, 























Cbz-Phe-Lys(BOC)-PABA-4AMQ (CDCl3) - Proton 
 
 


































Cbz-Lys(BOC)-Lys(BOC)-PABA-4AMQ (CDCl3) - Proton 
 
 




























































































Cbz-Lys(TFA)-Lys(TFA)-PABA-5AIQ (MeOD) - Proton 
 
 




































































































































Cbz-Phe-Lys(TFA)-PABA-4AMQ (MeOD) - Carbon 
 
 





Cbz-Lys(TFA)-Lys(TFA)-PABA-3AMQ (MeOD) - Carbon 
 
 

































Chapter 5: Conclusions and Future Work 
 
 
 We developed a convenient route to synthesize a series of probe candidates containing Z-
FK-PABA and Z-KK-PABA recognition dipeptides conjugated to four different aminoquinolines 
intended as potential lysosomotropic reporter molecules. To estimate the enzyme kinetics values 
associated with each probe candidate, a convenient HPLC method was developed and used to 
estimate the kcat/KM values using recombinant CTB and CTL. Both the Z-FK-PABA-AQ and Z-KK-PABA-
AQ peptides were efficient substrates of CTB.  In contrast, CTL hydrolyzed the Z-FK-PABA-AQ probes 
with exceptionally high kcat/KM values.   This suggests that a prodrug inspired approach using 
lysosomotropic reporters may have utility in detecting cysteine cathepsins activity in cell culture or 
in vivo. This is of particular importance toward the goal of developing substrate-based PET agents 
that release a radioactive reporter molecule in the lysosomes of cells expressing high levels of CTL. 
Future work would involve cell assays to determine the membrane permeability of the intact 
probes, specificity of each probe toward the cysteine cathepsins in cell lysates containing cellular 
enzymes, and experiments designed to quantify the retention of each quinoline reporter within the 
lysosome following treatment of cells with each probe candidate. Excitingly, the HPLC method 
developed for estimating the kcat/KM values in this thesis could be used to quantify the 
aminoquinoline isomers in each instance. 
 It is relevant to point out that a substrate-based approach using prodrug inspired chemistry 
designed to release a lysosomotropic reporter is applicable to various lysosomal enzymes including 
several aspartic and serine proteases.  In addition, other enzyme classes that operate within the 
lysosome, such as phosphatases and glycosidases, may be excellent candidates using a similar 
approach. 
